Pharmacological Blockade of the 20-HETE Receptor Lowers Blood Pressure and Alters Vascular Function in Mice with Vascular Smooth Muscle- Specific Overexpression of CYP4a12-20-HETE Synthase by Agostinucci, Kevin
Touro Scholar 
NYMC Student Theses and Dissertations Students 
3-30-2021 
Pharmacological Blockade of the 20-HETE Receptor Lowers 
Blood Pressure and Alters Vascular Function in Mice with 
Vascular Smooth Muscle- Specific Overexpression of 
CYP4a12-20-HETE Synthase 
Kevin Agostinucci 
Follow this and additional works at: https://touroscholar.touro.edu/nymc_students_theses 
 Part of the Medicinal and Pharmaceutical Chemistry Commons 
Recommended Citation 
Agostinucci, Kevin, "Pharmacological Blockade of the 20-HETE Receptor Lowers Blood Pressure and 
Alters Vascular Function in Mice with Vascular Smooth Muscle- Specific Overexpression of 
CYP4a12-20-HETE Synthase" (2021). NYMC Student Theses and Dissertations. 27. 
https://touroscholar.touro.edu/nymc_students_theses/27 
This Doctoral Dissertation - Open Access is brought to you for free and open access by the Students at Touro 
Scholar. It has been accepted for inclusion in NYMC Student Theses and Dissertations by an authorized 
administrator of Touro Scholar. For more information, please contact touro.scholar@touro.edu. 
Pharmacological Blockade of the 20-HETE Receptor 
Lowers Blood Pressure and Alters Vascular 
Function in Mice with Vascular Smooth Muscle-
Specific Overexpression of CYP4a12-20-HETE 
Synthase 
Kevin James Agostinucci 
A Doctoral Dissertation in the Program in Pharmacology 
Submitted to the Faculty of the 
Graduate School of Basic Medical Sciences 
in Partial Fulfillment of the Requirements 
for the Degree of Doctor of Philosophy 
at New York Medical College 
2021 
 
Pharmacological Blockade of the 20-HETE 
Receptor Lowers Blood Pressure and Alters 
Vascular Function in Mice with Vascular Smooth 
Muscle-Specific Overexpression of CYP4a12-20-
HETE Synthase 
Kevin James Agostinucci 
nudd�� 
Michal L. Schwartzman, Ph.D. 
Sponsor 
Vic or Garcia, Ph.D. 
Reader 
Alberto Nasjiletti, M.D. 
Reader 
Michael S. Wolin, Ph.D. 
Reader 
ii 
Date of approval 
03/30/2021
Acknowledgements 
The journey for the completion of my PhD at New York Medical College 
would not have been possible without the support of my colleagues, friends and 
family. First, I would like to thank Dr. Michal L. Schwartzman for the opportunity 
to complete my thesis under her mentorship. Dr. Schwartzman not only 
supported me throughout my time in her laboratory, but also challenged me, 
inspired me and facilitated me to be the best scientist I can be. I can’t thank you 
enough for everything you have done for me. I would like to thank the members 
of my thesis committee: Drs. Victor Garcia, Sachin Gupte, Alberto Nasjiletti, and 
Michael Wolin. I appreciate all the guidance, input, and assistance with regards 
to the completion of my thesis. To the past and present members of Dr. 
Schwartzman’s lab: Ankit Gilani, Sakib Hossain, Jonathan Pascale, Bibiana 
Iglesias, Elizabeth Villegas, Catherine D’addario, and Ghezal Froogh. Thank you 
for all the support you gave me throughout my time working in the lab. You all 
had valuable input that helped me complete some of my most difficult 
experiments. To all my friends I made during my time at NYMC: Juan Azcona, 
Roxanna Nahvi, Hannah Mulhall, Elizabeth Newman, Christina D’arco and Corey 
Gayletts. Thank you for all your support and encouragement. I will cherish all the 
moments we had together supporting each other in the lab and all the fun times 
we had at Captain Lawrence. To my parents, Karen and James and my sisters, 
Julie and Kristen, thank you for all your support throughout my academic career. 
You all have been there to give me the encouragement I need to help me push 
through the most difficult times. I love you all very much.     
iii 
iv 
Table of Contents 
Title page ................................................................................................................... i 
Approval page .......................................................................................................... ii 
Acknowledements ................................................................................................... iii 
Table of contents ..................................................................................................... iv 
List of figures ......................................................................................................... viii 
List of Abbreviations ................................................................................................ xi 
Abstract ................................................................................................................... xii 
Introduction and Background .................................................................................. 1 
 Biosynthesis of 20-HETE ................................................................................... 1 
20-HETE effects on the vasculature .................................................................. 3 
 Actions on vascular endothelium ....................................................................... 3 
 Actions on the vascular smooth muscle ............................................................ 5 
 Other actions of 20-HETE .................................................................................. 8 
 The 20-HETE receptor, GPR75 ......................................................................... 9 
20-HETE and hypertension .............................................................................. 12 
v 
Hypothesis ............................................................................................................. 16 
Specific Aims ......................................................................................................... 17 
Materials and Methods .......................................................................................... 19 
 Animals ............................................................................................................. 19 
 Blood Pressure Measurements ....................................................................... 19 
 Wired Myography ............................................................................................. 20 
 Pressure Myography ........................................................................................ 21 
 Sodium Excretion Studies ................................................................................ 22 
 Western Blot ..................................................................................................... 23 
 Reverse Transcription Polymerase Chain Reaction ....................................... 25 
20-HETE Measurements.................................................................................. 26 
 Statistics ........................................................................................................... 27 
Results ................................................................................................................... 29 
 Aim 1: To determine if smooth muscle-specific overexpression of Cyp4a12- 
20-HETE synthase causes hypertension and vascular dysfunction ............... 29 
vi 
Myh11-Cre(+/-)-Cyp4a12-Flox(+/wt) (Myh11-4a12) had significantly elevated 
Cyp4a12 levels in vessels that resulted in elevated 20-HETE ................. 29 
Myh11-4a12 mice are hypertensive and have impaired vascular function
 .................................................................................................................... 30 
Markers of smooth muscle cell contraction and NO signaling were altered 
in Myh11-4a12 mice. .................................................................................. 30 
 Aim 2: To determine if the vascular pathology in Myh11-4a12 mice is 20- 
 HETE-dependent .............................................................................................. 40 
Administration of AAA decreased systolic blood pressure and improves 
vascular function in mice with smooth muscle specific Cyp4a12 
overexpression. .......................................................................................... 40 
AAA administration improved media:lumen ratio but did not affect media 
thickness or cross-sectional area of RIA. .................................................. 42 
Markers of VSMC differentiation was elevated in Myh11-4a12 mice ....... 43 
No differences in collagen synthesis was observed between Myh11-4a12 
and wild type mice.. .................................................................................... 44 
 Aim 3: To explore cellular mechanisms underlying the increased contractility 
 of arteries from mice with smooth muscle-specific overexpression of Cyp4a12   
 .......................................................................................................................... 53 
vii 
No changes were observed in ACE RNA expression between wild type 
and Myh11-4a12 mice... ............................................................................. 53 
Myh11-4a12 mice had reductions in eNOS activation which was increased 
with AAA treatment..................................................................................... 53 
Administration of the 20-HETE receptor antagonist was able to reduce 
phosphorylation of myosin light chain.... .................................................... 55 
20-HETE was able to increase Rho-kinase activity which was attenuated
with AAA..... ................................................................................................ 55 
Discussion ............................................................................................................. 65 
Perspective and Significance ................................................................................ 81 
Reference: ............................................................................................................. 82 
viii 
List of Figures 
Figure 1: Myh11-4a12 mice display overexpression of Cyp4a12 in vessels ....... 32 
Figure 2: Myh11-4a12 mice have elevated Cyp4a protein in vessels ................. 33 
Figure 3: Myh11-4a12 mice display elevated 20-HETE. ...................................... 34 
Figure 4: Mice with smooth muscle-specific overexpression of Cyp4a12 are 
hypertensive. ......................................................................................................... 35 
Figure 5: Mice with smooth muscle-specific overexpression of Cyp4a12 have 
impaired relaxation ................................................................................................ 36 
Figure 6: Renal interlobar artery measurements of vascular remodeling are 
elevated in Myh11-4a12 mice ............................................................................... 37 
Figure 7: Baseline expression of myosin light chain phosphorylation at serine 19 
in mesenteric arteries were elevated in Myh11-4a12 mice. ................................. 38 
Figure 8: Baseline expression of phosphorylated and total eNOS was reduced in 
aortas of Myh11-4a12 mice................................................................................... 39 
Figure 9: Administration of a 20-HETE receptor antagonist (AAA) was able to 
lower blood pressure after 12 days ....................................................................... 45 
Figure 10: Plasma 20-HETE levels were unchanged after 12-day AAA treatment
 ............................................................................................................................... 46 
Figure 11: Urine volume and sodium excretion in WT and Myh11-4a12 mice 
treated with and without AAA ................................................................................ 47 
ix 
Figure 12: Vascular activity was improved after 12 days of AAA treatment ........ 48 
Figure 13: Myh11-4a12 mice had improved relaxation with AAA treatment ex 
vivo. ........................................................................................................................ 49 
Figure 14: Myh11-4a12 mice have an elevated media:lumen ratio that was 
reduced with AAA treatment, however, AAA did not reduce the thickness of the 
vessel. .................................................................................................................... 50 
Figure 15: Increases in markers of VSMC differentiation were observed in RIA of 
Myh11-4a12 mice. ................................................................................................. 51 
Figure 16: No differences in collagen expression were observed between Myh11-
4a12 and wild type mice ........................................................................................ 52 
Figure 17: No differences in ACE expression were observed between Myh11-
4a12 and wild type mice in mesenteric arteries. .................................................. 58 
Figure 18: Western blot analysis of eNOS and VASP phosphorylation in aorta. 59 
Figure 19: Phosphorylation of eNOS at serine 1177 after 12 days of AAA 
treatment was reduced in mesenteric arteries of Myh11-4a12 mice ................... 60 
Figure 20: Myh11-4a12 mice have elevated phosphorylation of myosin light chain 
that was reduced with 12 day AAA treatment ...................................................... 61 
Figure 21: ROCK1 protein expression was elevated in Myh11-4a12 mice ......... 62 
x 
Figure 22: Addition of AAA or Y-27632 prevented 20-HETE-mediated increase in 
myogenic tone of RIA from WT mice .................................................................... 63 
Figure 23: Absolute internal diameter (ID) and percent myogenic tone values of 
WT RIA at 80mmHg and 100mmHg ..................................................................... 64 
xi 

























Vascular Smooth Muscle Cell 
Endothelial Cell 
G-protein couple receptor 75
Systolic blood pressure 
Nitric Oxide 
Sodium Nitroprusside 
Inner diameter/outer diameter 
Smooth muscle myosin heavy chain 11 
Endothelial specific nitric oxide synthase 
Myosin light chain 
Transgelin/Sm22α 
Smooth muscle actin 2 
Rho-kinase 
Angiotensin converting enzyme 
Vasodilator-stimulated phosphoprotein 
Renal interlobar arteries 
Cross-sectional area 
Abstract 
20-hydroxyeicosatetraenoic acid (20-HETE) is the ω-hydroxylation product
of arachidonic acid catalyzed by CYP4A and 4F enzymes. 20-HETE is a 
vasoactive eicosanoid of the microcirculation exhibiting effects on both vascular 
smooth muscle cells (VSMC) and endothelial cells (EC). In VSMCs, 20-HETE’s 
bioactions include the stimulation of contraction, migration, and growth. In ECs, 
elevated 20-HETE is associated with reduced nitric oxide (NO) bioavailability, 
increased angiotensin converting enzyme (ACE) expression, and the promotion 
of inflammation. Recently in our laboratory, we identified GPR75 as a novel 
target of 20-HETE that promotes changes in blood pressure and vascular 
function. The aim of this study is to assess the consequences of VSMC-targeted 
overexpression of Cyp4a12, the primary 20-HETE producing enzyme in mice, on 
blood pressure, vascular function, and vascular remodeling. Moreover, we looked 
to examine whether the administration of a 20-HETE receptor antagonist 
reverses the vascular phenotype associated with elevations in 20-HETE.  
Mice with VSMC-specific overexpression of Cyp4a12 (Myh11-4a12) and 
their littermate controls (WT) were generated by crossbreeding Cyp4a12-flox 
mice (gifted by Dr. Schunck) with Myh11-Cre mice. Myh11-4a12 were 
administered AAA (10 mg.kg-1.day-1), a 20-HETE receptor antagonist, in the 
drinking water (vehicle). At the end of the experiments (12 days), renal interlobar 
arteries (RIA) and mesenteric arteries (MA) were harvested for the assessment 
of 20-HETE levels by LC-MS/MS, and vascular contractility, vasodilation, and 
remodeling using wire and pressure myography.  
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The Myh11-4a12 mice showed higher Cyp4a levels in MA compared to 
WT mice (6.5±0.71 vs 3.4±0.70; Cyp4a/β-actin p<0.05). Myh11-4a12 mice had 
increased 20-HETE levels in the MA (3334±891 vs. 545±197 pg/mg protein; 
p<0.05) and RIA (1859±376 vs 242±62 pg/mg protein; p<0.05), but, urine 20-
HETE levels were not different (117±9 vs. 93±2 pg/mL; p=0.18) when compared 
to WT. Myh11-4a12 mice displayed higher SBP compared to WT mice (145±2 
vs. 127±2 mmHg; p<0.05). Administration of AAA for 12 days normalized BP in 
Myh11-4a12 mice (124±2 mmHg vs. 147±4 mmHg, p<0.01). RIA from vehicle 
treated Myh11-4a12 mice displayed a higher media to lumen (M:L) ratio 
(0.277±0.025 vs 0.163 ± 0.009; p<0.01) and cross sectional area (CSA) 
(15114±1871 vs 10560±641 μm2; p<0.01) compared to WT mice on vehicle. 
Moreover, RIA from Myh11-4a12 mice on AAA exhibit a lower M:L ratio 
compared to Myh11-4a12 mice on vehicle (0.215 ± 0.013, p<0.05), but CSA was 
not different (14268 ± 1259 μm2). Higher constrictor responsiveness to 
phenylephrine (EC50: 1.63x10-7 ± 3.75x10-8 vs 5.00x10-7 ± 0.7.85x10-8 M, 
p<0.0001) and an impaired relaxation response to acetylcholine (Maximum 
response at 10-4 M: 65 ± 1 vs 83 ± 2 % relaxation, p<0.001) was observed in RIA 
from Myh11-4a12 mice compared to WT. Treatment of Myh11-4a12 mice with 
AAA diminished the constrictor responsiveness to phenylephrine (EC50 of 
4.22x10-7± 4.55x10-8 M, p<0.0001) and improved the relaxation in response to 
acetylcholine (92 ± 2 % relaxation, p<0.001). Myh11-4a12 mice had elevated 
phosphorylation of myosin light chain compared to WT mice (1.60 ± 0.23 vs 1.00 
± 0.06, Ser19 p-MLC/total MLC fold change, p<0.05). Myh11-4a12 mice on AAA 
xiii 
exhibited a decrease in myosin light chain phosphorylation compared to Myh11-
4a12 mice on vehicle (0.94 ± 0.11, Ser19 p-MLC/total MLC fold change, p<0.05). 
Upstream of myosin light chain is Rho kinase (ROCK). Expression of ROCK1 
was assessed in RIA and Myh11-4a12 mice had increased ROCK1 expression 
compared to WT mice (1.60 ± 0.21 vs 1.00 ± 0.18, ROCK1/β-tubulin fold change, 
p<0.05) but AAA was unable to significantly reduce the expression (1.48 ± 0.20, 
ROCK1/β-tubulin fold change). Pressure myography was performed to assess 
20-HETE receptor antagonism on ROCK activity. In RIA from WT mice, 20-HETE 
administration promoted a greater myogenic response and both AAA and ROCK 
inhibitor (Y-27632) inhibited the 20-HETE response in relation to the myogenic 
tone.  
The results of this study suggest that VSMC specific overproduction of 
Cyp4a12 and 20-HETE promotes increase in blood pressure and changes in 
vascular reactivity. 20-HETE receptor antagonism was capable of reversing the 
vascular pathology in mice with elevated 20-HETE presumably through inhibition 
of ROCK activity.   
xiv 
1 
Introduction and Background 
Biosynthesis 20-HETE 
20-HETE is the ω-hydroxylation product of arachidonic acid catalyzed by
cytochrome P450 enzymes (CYP4A/4F), with Cyp4a12 being the primary 20-
HETE synthetase in mice. 20-HETE can be measured in tissue and in biological 
fluids. The vascular system is a primary site of 20-HETE production and it can be 
found in conduit arteries such as the aorta (Costa et al., 2018; Soler et al., 2018), 
and resistant arteries such as mesenteric arteries (Zhang et al., 2001), renal 
microvessels (Croft et al., 2000) and cerebral microvessels (Gebremedhin et al., 
1998, 2000). Within each vessel type, 20-HETE is generated in the vascular 
smooth muscle cells (VSMC) (Harder et al., 1994; Gebremedhin et al., 1998) and 
endothelial cells (EC) (Zhu et al., 2002; Chen et al., 2016; Joseph et al., 2017). 
Circulating cells, such as endothelial progenitor cells, platelets, and myeloid cells, 
can also generate 20-HETE (Rosolowsky et al., 1996; Christmas et al., 2001; 
Wang et al., 2006; Tsai et al., 2011; Chen et al., 2014). The kidney tubules is 
another site of 20-HETE production where it can be measured within the tissue 
and contribute to the amount present in the urine (Gilani et al., 2020). Proximal 
tubules are the predominate sources of 20-HETE in the kidney tubules, with 
some production occurring in the thick ascending loop of henle (TALH), distal 
convoluted tubule and the collecting tubules (Carroll, M. A., Sala, A., Dunn, C.E., 
McGiff, J.C., 1991; Omata et al., 1992). Heart, brain, lung and adipose tissue are 
more examples of tissues that can produce 20-HETE (Zhu et al., 2002; Chuang 
et al., 2004; Joseph et al., 2017; Gilani et al., 2018, 2021). 
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Several factors can play a role in either the increase or decrease 
production of 20-HETE. Androgens are well known for inducing Cyp4a 
expression and their administration has been established as a model for global 
overexpression of 20-HETE in mice and rats (Holla et al., 2001; CC Wu et al., 
2013). PPAR𝛄  agonists, such a Clofibrate, and parathyroid hormone can 
increase Cyp4 activity (Roman et al., 1993; Ribeiro et al., 1994; Silverstein et al., 
1998). Angiotensin II, norepinephrine and endothelin-1 all facilitate increase in 
20-HETE by promoting increases in intracellular calcium which is necessary for
cytosolic phospholipase A2 activity and arachidonic acid release from 
phospholipids (Muthalif et al., 1996; Hercule and Oyekan, 2000; Parmentier et 
al., 2001; Tsai et al., 2011). Factors such as carbon monoxide or nitric oxide 
(NO) decrease 20-HETE production by binding to the heme moiety of Cyp4a 
enzyme to prevent its formation (Wang et al., 2003; Kaide et al., 2004).  
Several cytochrome P450 enzymes have been shown to be involved in 
the production of 20-HETE across rodents and humans. In mice, Cyp4a10, 
Cyp4a12, and Cyp4a14 have some capacity to produce 20-HETE, with Cyp4a12 
having the greatest capacity (Capdevila and Falck, 2000; Roman, 2002; Muller et 
al., 2007). The 20-HETE-producing enzymes in rats include Cyp4a1, Cyp4a2 and 
Cyp4a3 (Nguyen et al., 1999; Hardwick, 2008). The main 20-HETE-producing 
enzymes in humans are CYP4A11 and CYP4F2 (Powell et al., 1998; Lasker et 
al., 2000).  
 3 
20-HETE effects on the vasculature 
As indicated above, the vasculature is a significant source of 20-HETE 
production and a prime target of its actions. 20-HETE is a vasoactive lipid 
mediator affecting vascular tone and inflammation through actions on the 
vascular endothelium and the smooth muscle.  
 
Actions on vascular endothelium 
 The vascular endothelium is a single layer of cells containing many factors 
that can diffuse to the smooth muscle to allow for changes in tension of vessels. 
20-HETE overproduction has been shown to act in the endothelium to promote 
constriction. These actions include: 1) reduced NO bioavailability, 2) actions on 
renin-angiotensin-system, and 3) activation of endothelium inflammation 
processes.  
 NO is produced in the endothelium, by endothelial-specific nitric oxide 
synthase (eNOS), which is expelled to the VSMCs to exert its effect. 20-HETE 
can act on different parts of this signaling pathway to lower NO bioavailability. 20-
HETE has a direct inhibitory effect on eNOS. Both in vitro and in vivo, 20-HETE 
has been shown to inhibit activation of eNOS by preventing phosphorylation at 
serine 1179 (Cheng et al., 2008; Inoue et al., 2009). Furthermore, 20-HETE has 
been shown to cause eNOS uncoupling with HSP90 via NF-κB-IKK signaling 
pathway (Cheng et al., 2010). 20-HETE also has indirect mechanisms which 
lower the bioavailability of NO. 20-HETE has been shown to increase superoxide 
production through NADPH oxidase-dependent and -independent mechanisms 
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(Guo et al., 2007; Medhora et al., 2008). The increase in superoxide shunts NO 
to produce peroxynitrite which prevents it from migrating to the VSMCs to cause 
dilation (Medhora et al., 2008).  
 20-HETE has been shown to increase the expression and activity of 
angiotensin converting enzyme (ACE). Induction of 20-HETE production in vivo 
and in vitro has been shown to increase endothelial ACE expression via NF-kB-
IKK pathway (Cheng et al., 2012; Garcia et al., 2016). Increases in ACE 
expression were accompanied by increases in angiotensin II levels which can act 
on its own receptor to cause changes in vessel function (Sodhi et al., 2010).   
 Vascular inflammation is another effect of 20-HETE in the endothelium. 
Reports have shown that 20-HETE can increase inflammatory markers such as 
IL-6 and IL-8 and adhesion molecules such as ICAM (Guo et al., 2007; Ishizuka 
et al., 2008). 20-HETE has been shown to increase NF-κB and MAPK, which 
facilitate the production of inflammatory markers (Guo et al., 2007; Ishizuka et al., 
2008). The inflammatory state of the vessels can be reversed with administration 
of 20-HETE synthase inhibitor.  
 Angiogenesis is the process of making new blood vessels from preexisting 
vessels. This process requires the coordinated action of the endothelium to 
branch out from the vessel, migrate away from the branch point and form a tube 
structure. 20-HETE in vitro has been shown to increase EC proliferation as a 
result of both increases in VEGF and HIF-1α (Guo et al., 2007, 2009). These 
actions relied on an increased oxidative environment which resulted in the 
activation of the NF-κB pathway. Furthermore, 20-HETE in vivo has been shown 
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to upregulate angiogenesis by promoting endothelial progenitor cell homing and 
adhesion to the EC (Chen et al., 2014, 2016).   
 
Actions on vascular smooth muscle 
The VSMC is the contractile unit within the vasculature. It is located in the 
tunica media adjacent to ECs. Contraction caused by VSMCs play a role in 
maintaining blood flow to tissues. 20-HETE has been documented to change the 
VSMC phenotype by either: 1) increased sensitivity to contractile stimuli and 2) 
increased vessel wall thickness. These changes in VSMC physiology ultimately 
reduces blood flow, reduce compliance and increases in blood pressure.   
VSMCs are responsible for causing contraction to redirect blood flow to 
tissue with higher metabolic demand. It is important for VSMC to be sensitive to 
specific stimuli that can promote changes in lumen diameter so tissues can 
receive a consistent blood flow. Autoregulation is an intrinsic property of a vessel 
where blood flow is maintained despite changes in pressure in the system. 
Autoregulation relies on the ability of the vessel to contract when it senses 
increase transluminal pressure, defined as the myogenic response (Davis et al., 
1992). 20-HETE has been documented, in cerebral and renal circulation, to 
promote contraction which shift the autoregulation curve to the right so vessels 
maintain a constant flow at higher pressures (Zou et al., 1994; Gebremedhin et 
al., 2000). Inhibition of 20-HETE synthesis has been shown to cause dilation and 
prevent the vessel’s autoregulatory ability.  
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 20-HETE has been shown to promote contraction in VSMCs by 1) 
increasing intracellular calcium and 2) activating Rho kinase. Calcium signaling is 
important because it is the initial step to cause VSMCs contraction. Calcium 
enters the VSMC through the L-type calcium channel which increase intracellular 
calcium levels. The increase in intracellular calcium activates calmodulin which 
then activates myosin light chain kinase (Tansey et al., 1994; Raina et al., 2009). 
Myosin light chain kinase phosphorylates the myosin light chain which is the 
necessary signal in order to initiate excitation-contraction in the VSMCs (Driska 
et al., 1981). The mechanisms by which 20-HETE affects intracellular calcium 
levels are through inhibition of the large-conductance Ca2+-activated K+-channel 
(BKCa2+) (Zou et al., 1996; Lauterbach et al., 2002; Fan et al., 2013; Toth et al., 
2013) and activation of L-type calcium channels (Gebremedhin et al., 1998).  
 Mechanisms exist within the VSMC to terminate signaling for contraction. 
Myosin light chain phosphatase is the protein within the VSMC that can remove 
the phosphate group off of myosin light chain and inhibit contraction (Wang et al., 
2009). The activity of myosin phosphatase is regulated by Rho-kinase (ROCK). 
The activation of ROCK is initiated by GPCR-mediated mechanisms to activate 
Rho-GTP which removes the inhibitory subunit on ROCK (Swärd et al., 2003). 
20-HETE has been reported to increase the activity of ROCK and increase 
myosin light chain phosphorylation (Randriamboavonjy et al., 2003). The 
inhibition of mechanisms to remove phosphate from myosin light chain sensitizes 
VSMCs to other constrictor stimuli.    
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 The vascular wall is dynamic in that it can respond to external cues to 
change its architecture. In the normal state, the vessel is quiescent, but in the 
presence of certain stimuli, the vessel can undergo processes which allow it to 
thicken to compensate for the elevated pressure (Li et al., 1994; Garcia, et al., 
(2015b)). The consequences of remodeling in the vessels include decreases in 
compliance, reduced blood flow and ultimately even further increase in blood 
pressure. 20-HETE promotes changes in vascular wall remodeling without 
contribution to sympathetic nerve activation (Ding et al., 2013), as well as 
increase in ACE (Garcia, et al., (2015b)). Thus, 20-HETE displays its own 
signaling mechanism to promote thickening of the vascular wall. There are 
several signaling mechanisms which contribute to the mitogenic effect of 20-
HETE. First, 20-HETE causes VSMC migration by activation of the MAP-kinase 
and PI3K/Akt signaling pathways (D Stec et al., 2007). Proliferation is also 
increased with 20-HETE. In vitro experiments with norepinephrine stimulation 
suggests that 20-HETE promotes proliferation via MAP-kinase signaling (Uddin 
et al., 1998; Kalyankrishna and Malik, 2003). 20-HETE has also been shown to 
cause proliferation in vivo. In an experiment by Orozco and colleagues (2013), 
they used a balloon injury model to promote carotid artery thickening which was 
prevented by administration of Cyp4a inhibitors (Orozco et al., 2013).  
 Another contributor to the changes in vascular wall remodeling is through 
changes in the architecture of the extracellular matrix (ECM). The ECM is 
comprised of structural proteins that give the vessels its ability to withstand 
changes in wall tension. The actions of 20-HETE within the ECM includes 
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increased collagen IV deposition (Ding et al., 2013) and elastin degradation 
(Soler et al., 2018). 20-HETE can increase reactive oxygen species in VSMCs 
(Lakhkar et al., 2016) which can act as a second messenger for the increased 
production of MMP12 that degrades elastin in conduit arteries (Soler et al., 
2018). These actions contribute to the reduction in compliances that result in 
elevated blood pressure.  
    
Other actions of 20-HETE 
The actions of 20-HETE are not limited to maintenance of vascular tone 
within the central circulation. 20-HETE has numerous actions within structures of 
the kidney that result in changes in plasma osmolality. In renal preglomerular 
vessels, 20-HETE has been shown to sensitize vessels to phenylephrine-induced 
constriction and impaired relaxation after acetylcholine administration (CC Wu et 
al., 2013). Impairment in preglomerular microvessel activity resulted in reductions 
in glomerular filtration rate (Pandey et al., 2017) and an increase in proteinuria 
(Inoue et al., 2009). These changes resulted in an elevation in plasma osmolality 
and, ultimately, increases in blood volume. 20-HETE is produced and has actions 
within the kidney tubules (Omata et al., 1992; Lin et al., 1995). 20-HETE has 
been shown to act on different transporters in the nephron and, depending on the 
transporter, has a different effect on salt excretion. 20-HETE pro-natriuretic effect 
includes inhibition of Na+-K+-ATPase (Schwartzman et al., 1985; Nowicki et al., 
1997) in the proximal tubule and sodium-potassium-chloride cotransporter 
(NKCC2) in the thick ascending limb (Amlal et al., 1996, 1998). Furthermore, 20-
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HETE also can increase the activity of the sodium chloride transporter resulting 
in an anti-natriuretic effect (Savas et al., 2016; Gilani et al., 2020).  
 20-HETE also has actions to promote increases in body weight gain and 
changes in insulin signaling. In human subjects, correlations have been shown 
between elevated 20-HETE in the urine and increased BMI. Mouse models of 
Cyp4a12 overexpression have also shown that elevated 20-HETE promotes 
increases in body weight and insulin resistance when on a high-fat diet (Gilani et 
al., 2018, 2021). These actions of global expression of Cyp4a12 were reversed 
when mice were administered 20-SOLA (a 20-HETE antagonist) (Gilani et al., 
2018, 2021). The consequence of 20-HETE overproduction after a high-fat diet 
shows changes in insulin signaling and hyperglycemia. One report shows that 
overexpression of CYP4F2 promotes hyperglycemia on a normal diet (Lai et al., 
2012). Hyperglycemia can be contributed to changes in insulin signaling. Reports 
have shown that 20-HETE can affect activation of the insulin receptor and/or the 
ability of IRS-1 to dock on the insulin receptor (Li et al., 2014; Gilani et al., 2018, 
2021). One report shows that 20-HETE can inhibit glucose-mediated insulin 
secretion through the FFAR1 receptor (Tunaru et al., 2018).  
 
The 20-HETE receptor, GPR75  
The cellular mechanisms underlying the bioactions of 20-HETE have been 
extensively studied; however, what remains to be elucidated is the up-stream 
factors that result in the initiation of 20-HETE’s signaling cascade. The first report 
to demonstrate 20-HETE’s proximal signaling was published by Garcia and 
 10 
colleagues (2017). They were the first to show that 20-HETE binds to a cell 
surface receptor, namely GPR75, and to report the proximal signaling 
mechanism through which 20-HETE causes hypertension and vascular 
dysfunction (Garcia et al., 2017).  
 GPR75 is a 7-transmembrane G-protein coupled receptor (GPCR) that is 
classified as an orphan receptor (Garcia et al., 2017). The gene for this receptor 
was identified on the 2p16 chromosome and translation of this gene results in a 
540 amino acid GPCR with a molecular weight of 59 kDa (Tarttelin et al., 1999). 
A unique feature of this receptor is its c-terminal tail that is 169 amino acids in 
length, which is longer than most GPCRs (Pease, 2006). The extended tail 
allows for docking of proteins to initiate complex signaling cascades. In several 
different cell models, GPR75 has been shown to complex with Gq, hic-5, c-Src 
and GIT-1 (Ignatov et al., 2006; Garcia et al., 2017).  
 The expression of GPR75 can be found in the retinal pigmented 
epithelium, brain and heart (Tarttelin et al., 1999; Dedoni et al., 2018; Gonzalez-
Fernandez et al., 2020). GPR75 expression is also detected in the vascular 
endothelium and smooth muscle (Garcia et al., 2017; Gonzalez-Fernandez et al., 
2020), pancreatic islets (Liu et al., 2013) and prostatic cancer cells (Cárdenas et 
al., 2020). Within these cell types, it has been shown that activation of GPR75, 
mediated by Gq, increases intracellular calcium which then activates downstream 
signaling including phospho-ERK1/2 (Ignatov et al., 2006; Garcia et al., 2017; 
Dedoni et al., 2018; Cárdenas et al., 2020). Garcia et. al. (2017), demonstrated 
that in VSMCs 20-HETE-GPR75 pairing results in a PKC- and c-Src-mediated 
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phosphorylation of BKCa2+ channels leading to their inactivation (Garcia et al., 
2017). 
 The effects of 20-HETE on the cardiovascular system through its binding 
to GPR75 is a new area of research. There is evidence that individuals with a 
permutation of the 2p chromosome (the site of GPR75 gene) are more likely to 
be non-responders to current hypertensive therapies (Padmanabhan et al., 
2006). Thus, exploring the effects of GPR75 on blood pressure can be useful. 
Garcia et. al. (2017) showed that mice with overexpression of Cyp4a12 were 
hypertensive and knocking down GPR75 with shRNA normalized blood pressure 
(Garcia et al., 2017). Furthermore, pharmacological antagonism of the 20-HETE-
GPR75 pairing has been shown to blunt 20-HETE-dependent actions in the 
cardiovascular system as well as in disease models (Pandey et al., 2017; Gilani 
et al., 2018, 2021; Soler et al., 2018). In a report by Sedlákova et. al. (2018), they 
generated a rat model with elevated 20-HETE and angiotensin II that 
dramatically increased the blood pressure. They administered AAA (a novel 20-
HETE receptor antagonist) which was able to lower the blood pressure of these 
rats (Sedláková et al., 2018). In another report, AAA was shown to blunt the 
effects of 20-HETE on the metastatic features in a prostate cancer cell line 
(Cárdenas et al., 2020). Thus, pharmacological antagonism may be a therapeutic 





20-HETE and hypertension 
The link between 20-HETE and hypertension has been well established 
across numerous animal models. The use of animal models has been vital in 
understanding the actions of 20-HETE in vivo. Animal models have shown the 
consequences of elevated 20-HETE levels on vascular and renal function. Some 
examples of animal models include: 1) Cyp4a12-tg, 2) DHT-pellet-treated mice, 
3) Cyp4a14-/-, 4) spontaneously hypertensive rats, and 5) Dahl salt-sensitive 
hypertensive rats.  
 The Cyp4a12-tg mouse has elevated 20-HETE production in the presence 
of doxycycline (CC Wu et al., 2013). This mouse was engineered to have 
Cyp4a12 expression controlled by the tetracycline inducible promoter. This is 
advantageous in experiments where control of 20-HETE production is necessary. 
Administration of doxycycline (DOX) in these mice resulted in changes in blood 
pressure and vascular reactivity that are dependent on 20-HETE (CC Wu et al., 
2013; Ding et al., 2013; Gilani et al., 2021).  
 Androgens are a known inducer of Cyp4a expression and 20-HETE. Two 
animal models of androgen-inducible 20-HETE include the DHT-pellet-treated 
mouse and the Cyp4a14-/- mouse. DHT-pellets are implanted subcutaneously in 
the mouse which allows for global overproduction of Cyp4a12 and 20-HETE that 
can be observed in male and female mice (Singh et al., 2007; CC Wu et al., 
2013; Garcia et al., (2015a)). The Cyp4a14-/- mouse also resulted in increased 
Cyp4a12 and 20-HETE. The deletion of the Cyp4a14 gene promotes androgen-
driven Cyp4a12 expression that is only observable in male mice (CC Wu et al., 
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2013; Ding et al., 2013; Pandey et al., 2017). Both these experimental models 
are associated with elevation in blood pressure, altered vascular function and 
kidney function.  
 The Tie2-CYP4F2-Tr mouse is a genetically engineered mouse that 
displays overexpression of the human CYP4F2 gene specifically in EC (Cheng et 
al., 2014). These mice have elevated 20-HETE in EC of tissues including kidney, 
lung, liver, heart and aorta. The Tie2-CYP4F2-Tr displayed changes in the 
angiogenic phenotype but do not have any differences in blood pressure 
compared to wild type mice (Cheng et al., 2014).  
 The spontaneously hypertensive rat (SHR) is documented to have 
elevated Cyp4a1, Cyp4a2, and Cyp4a3 levels which all contribute to the 
elevation of 20-HETE (Sacerdoti et al., 1989; Roman, 2002; Dunn et al., 2008). 
This rat model has been documented to have increases in blood pressure, 
vascular reactivity and changes in cerebral and renal blood flow (Zhang et al., 
2001; Dunn et al., 2008). The changes in cerebral circulation were associated 
with cerebral infarcts (Dunn et al., 2008).  
The Dahl salt-sensitive hypertensive rat is an example of an animal model 
where lower 20-HETE levels result in elevated blood pressure. In the medullary 
area of the kidney, Cyp4a expression was reduced (Stec et al., 1996). 
Reductions in Cyp4a and 20-HETE were associated with changes in transluminal 
voltage due to uninhibited activity of the NKCC2 cotransporter (Roman and 
Kaldunski, 1991; Ito and Roman, 1999). This increased salt and fluid 
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reabsorption which contribute to the elevation in blood pressure (J Wu et al., 
2013).     
Hypertension is defined as the chronic elevation of blood pressure, 
>130/80mmhg (CDC, 2020). In the United States, nearly half of adults fit into this 
definition with men, African Americans and/or Hispanics having a greater risk of 
developing hypertension (CDC, 2020). Individuals with elevated blood pressure 
are at a greater risk of coronary heart disease, stroke, and renal failure 
(Gosmanova et al., 2016). Current therapies, such as ACE inhibitions, diuretics, 
beta-blockers, and calcium channel blockers target their respective signaling 
mechanism to reduce blood pressure. However, approximately one-third of the 
population do not see a successful outcome from using hypertensive medications 
(Cushman et al., 2002). Thus, new therapies are in need to improve the clinical 
outcome within these patients.  
 CYPs are well known to have genetic variations that are correlated with 
increasing blood pressure in humans (Rocic and Schwartzman, 2018). Genetic 
polymorphisms have been shown to change the catalytic activity of these 
enzymes. For example, the T8590C SNP for CYP4A11 and the V433M in 
CYP4F2 have been shown to be associated with hypertension (DE Stec et al., 
2007; Laffer et al., 2008; Ward et al., 2008; Huang et al., 2020). Changes in 
catalytic activity of these enzymes may affect 20-HETE levels which drives the 
changes in blood pressure. 20-HETE has been shown to correlate with certain 
factors in hypertensive patients. 20-HETE has been shown to positively correlate 
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with blood pressure in patients with salt-sensitive hypertension (Laffer et al., 
2003), and negatively correlate with flow-dependent dilation (Ward et al., 2004). 
 The effects of 20-HETE on blood pressure and sodium handling are 
complex. On one hand, it inhibits ion transport along the nephron leading to 
natriuresis thus contributing to anti-hypertensive mechanisms. For example, Dahl 
salt-sensitive hypertensive rats are known to have decreased Cyp4a expression 
and 20-HETE production which is associated with higher blood pressure (Stec et 
al., 1996). 20-HETE in the kidney tubule has been shown to inhibit the NKCC2 
co-transporter, which is occurring at a lower frequency in the Dahl salt-sensitive 
rat (Escalante et al., 1991, 1994; Ito and Roman, 1999).  On the other hand, 
global overexpression models of 20-HETE, including 5-dihydrotestosterone 
treated mice (Ding et al., 2013), Cyp4a12 transgenic mice (Garcia, et al., 
(2015b)), and the Cyp4a14-/--knock out mouse (Holla et al., 2001; CC Wu et al., 
2013) all have been shown to promote vasoconstriction and increases in 
peripheral vascular resistance and blood pressure due to systemic elevations of 
20-HETE.  
The proposed studies are aimed at identifying the cellular mechanism 
(GPR75-mediated) by which 20-HETE affects VSMC contractility and 
determining the role of VSMC-derived 20-HETE in the control of blood pressure. 
The influence of 20-HETE in the regulation of blood pressure makes it an 
attractive target for therapeutic intervention. The discovery of GPR75 as the 20-





Smooth muscle-specific overexpression of Cyp4a12-20-HETE-synthase 




Aim 1: To determine if smooth muscle-specific overexpression of Cyp4a12-
20-HETE synthase (Myh11-4a12) causes hypertension and vascular 
dysfunction 
a) Establish transgenic mice with smooth muscle-specific overexpression 
of the Cyp4a12-20-HETE synthase (Myh11-4a12). 
b) Characterize the phenotype of the Myh11-4a12 with respect to blood 
pressure and vascular function including contractility, vasodilatory 
response and remodeling.  
 
Aim 2: To determine if the hypertension and vascular pathology in Myh11-
4a12 mice are 20-HETE-dependent  
a) Use a 20-HETE receptor antagonist to determine whether the 
hypertensive and vascular phenotype of the Myh11-4a12 mice are 20-
HETE dependent 
 
Aim 3: To explore cellular mechanisms underlying the changes in vessel 
reactivity of arteries from mice with smooth muscle-specific 
overexpression of Cyp4a12   
a) Assess expression of known 20-HETE targets (e.g., eNOS, ACE, Rho-
kinase, MLC) in vascular beds including renal microvessels and 
mesenteric arteries by qRT-PCR and Western blot. 
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b) Examine whether activation of the Rho-kinase underlies the contractile 
phenotype of arteries from Myh11-4a12 mice using pressure 
myography, 20-HETE receptor antagonists and a Rho-kinase inhibitor.   
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Materials and Methods 
 
 
Animals: Mice with VSMC-specific overexpression of Cyp4a12 were generated 
by crossing mice with cre-recombinase expression driven by the VSMC-specific 
myosin heavy chain promoter (Myh11-Cre+/-) and Cyp4a12-flox mice (Cyp4a12-
flox+/+). Cyp4a12-flox+/+ mice contain loxP sites flanking a regulatory region of the 
Cyp4a12 promoter. In the presences of cre-recombinase, the regulatory region is 
removed and unregulated Cyp4a12 production can occur. Pups generated were 
divided into wild type (WT: Myh11-4a12-Cre-/--Cyp4a12-flox+/wt) or positive mice 
(Myh11-4a12: Myh11-Cre+/--Cyp4a12-flox+/wt). All mice were housed in static 
cages and fed standard chow. Experiments were conducted on mice between 
the ages of 2-4 months. A novel water-soluble 20-HETE receptor antagonist, N-
disodium succinate-20-hydroxyeicosa-6(Z),15(Z)-diencarboxamide (AAA), was 
used to assess the relevance of 20-HETE in the phenotype of these mice. Mice 
were divided into three groups: 1) Wild-type – vehicle; 2) Myh11-4a12 – vehicle; 
and 3) Myh11-4a12 – AAA treatment. Baseline SBP was measured before 
administration of AAA. Mice were administered either vehicle (tap water) or AAA 
at a dose of 10mg.kg-1.day-1 in drinking water. Systolic blood pressure was 
measured on days 0, 4, 8, and 12. After the last blood pressure measurement, 
mice were sacrificed and tissues were collected for physiological and 
biochemical analysis. 
 
Blood Pressure Measurements: Systolic blood pressure (SBP) was measured 
using CODA non-invasive tail-cuff method (Kent Scientific, Torrington, CT). The 
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CODA tail-cuff system utilizes volume-pressure recording (VPR) technology to 
measure the expansion of the mouse’s tail due to the return of blood flow after 
occlusion. All cuffs and bladders were checked for patency before measurements 
were taken. A warming plate was set to 32-35o Celsius to maintain body 
temperature during the measurement. The CODA software was set to have a 
deflation time of 20 seconds and allowed measurements of ≥ 15μL. Mice 
underwent 30 inflation-deflation cycles. The first 5 cycles were dedicated for 
acclimation and was not used in blood pressure determination. The last 25 cycles 
were used for blood pressure measurements. All cycles were carefully examined 
and cycles were removed if artifacts were identified in the measurement. All mice 
were allowed 5-7 days to undergo the tail-cuff procedure without collecting data. 
Baseline measurements per mouse were obtained by taking the average SBP on 
three separate days. Blood pressure measurements on AAA were measured on 
days 0, 4, 8, and 12.  The CODA system is able to measure SBP within ±10% of 
actual value. 
 
Wired Myography: Phenylephrine-induced contraction, as well as acetylcholine 
and SNP induced relaxation were performed on renal interlobar arteries (RIA). 
Kidneys were taken out of mice and were carefully dissected in a dish containing 
Kreb’s buffer. Isolated vessels were mounted onto wires in a chamber of a 
multivessel myograph. Before conducting experiments, vessels were allowed to 
sit in a bath containing Kreb’s buffer, maintained at 37oC, and constantly being 
bubbled with 95/5% O2/CO2 for 30-60 minutes. All vessels were set to an internal 
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circumference that is 90% of what the circumference would be at 100mmHg. 
Isometric tension was measured throughout the experiment. Cumulative 
phenylephrine dose-response experiments were performed. Phenylephrine was 
administered at half-dose intervals from (10-9-10-4 M) directly into the tissue bath. 
Tension was represented as a percentage of the maximal response at 10-4 M 
phenylephrine. Percent maximal response % = [(tension at a dose Phe/(tension 
10-4 M Phe - baseline tension))*100]. Acetylcholine or sodium nitroprusside 
(SNP) relaxation experiments were also performed. Before acetylcholine or SNP 
administration, precontraction was achieved by administering phenylephrine (10-6 
M) to the vessel bath. Acetylcholine (10-8-10-4 M) or SNP (10-9-10-5 M) was 
administered in a cumulative dose-dependent fashion after phenylephrine 
induced precontraction. The percent relaxation was calculated by subtracting the 
tension after a dose of acetylcholine or SNP from the tension generated from 10-6 
M phenylephrine, divided by the difference between the baseline tension and 10-6 
M phenylephrine. Percent relaxation % = [(tension at a dose of Ach or SNP [M] - 
tension at [10-6 M] Phe)/ (tension at [10-6 M] Phe - baseline tension)*100].  
 
Pressure Myography: Renal interlobar arteries were dissected in the same 
manner as for wired myography experiments. Living Systems Instrumentations 
(St. Albans City, VT) pressure myograph was used to induce pressures within the 
lumen of the vessel. The distances of the inner and outer diameters were 
measured using video edge detection. One end of the renal interlobar artery was 
mounted onto a glass canula and the other side was ligated closed. The vessel 
 22 
was allowed to equilibrate for one hour at 37oC in Kreb’s buffer bubbled with 
95/5% O2/CO2. For measurements of vascular wall thickness, internal pressures 
of 100mmHg were induced on normotensive vessels and 140mmHg on 
hypertensive vessels. Measurements of outer diameter (OD) and inner diameter 
(ID) under passive conditions were used to calculate media thickness [(OD - 
ID)/2], media:lumen ratio [(OD - ID)/ID], and medial cross-sectional area [CSA 
(π/4) x (OD2 - ID2)]. For measurements of myogenic response, only WT vessels 
were used. Each vessel underwent 5 consecutive treatments in the following 
order: 1) vehicle only (100% ethanol), 2) 20-HETE (10 μM), 3) 20-HETE + AAA 
(10 μM), 4) 20-HETE + Rho-kinase inhibitor (Y-27632, 10 μM), and 5) 20-HETE 
+ AAA + Rho-kinase inhibitor. Passive stretch of vessels was also assessed 
immediately after the treatments by measuring the internal diameter of the vessel 
in a calcium-free Kreb’s solution. Vessels were subjected to pressures of 0, 20, 
40, 60, 80 and 100 mmHg and ID was measured at each pressure. The Absolute 
and normalized ID were determined after experiments were concluded. The 
normalized ID was represented as a percentage and calculated as follows: 
normalized ID = (absolute ID/passive ID)*100.  
 
Sodium Excretion Studies: On the last day of AAA treatment, mice were 
individually housed in metabolic cages to collect urine (Hatteras instruments). 
Twenty-four-hour urine collection was taken and urine samples were stored at -
80oC until time to measure urinary sodium. Water consumption and urine volume 
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were measured to assess fluid balance. Urinary sodium measurements were 
performed using flame photometry.  
 
Western blots: Mesenteric arteries were taken out and carefully dissected in ice-
cold MOPS buffer to remove fat tissue. Vessels were flash-frozen in liquid 
nitrogen and stored at -80oC. Tissues were lysed by crushing vessels in liquid 
nitrogen followed by homogenization in RIPA buffer containing protease and 
phosphatase inhibitor. Lysates were allowed to sit on ice for 15 minutes before 
centrifugation. Lysates were spun at 10,000 RPM for 15 minutes at 4oC and 
supernatant was collected for western blot experiments. Protein estimation was 
performed using BCA assay. Equal amounts of protein were loaded onto a 10%-
polyacrylamide gel and ran at 125V. Proteins were transferred onto a PVDF 
membrane using methanol-glycine-tris-base transfer buffer. After transfer, 
membranes were blocked in TBS buffer containing 1% bovine serum albumin for 
1 hour. Cyp4a (1:1000 – Santa Cruz – cat#: sc-271983), Myh11 (1:1000 – 
Abcam – cat#: ab125884), ROCK1 (1:1000 – Sigma – cat#: HPA007567), Serine 
1177 p-eNOS (1:100 – cell signaling technology – cat#: 9571S), total eNOS 
(1:100 - BD bioscience – cat#: 610297), β-Tubulin (1:2000 - Invitrogen - cat#: 
MA5-16308) and β-actin (1:5000 - Cell Signaling Technology – cat#: 4967) were 
diluted in 1% casein/TBST solution and membranes were submerged in the 
antibody solution overnight on a shaker at 4oC. Secondary antibodies (Li-Cor 
biotechnology) were diluted (1:15,000) in 1% casein/TBST solution and 
membranes were allowed to incubate for 2 hours at room temperature on a 
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shaker. Membranes were visualized on the Li-Cor Odyssey Clx membrane 
scanner and quantified using ImageStudio software version 5.2.5. All western 
blots were represented as a fold changed compared to wild type. To calculate 
this, first the ratio between the protein of interest and the loading control (β-actin 
or β-tubulin) was determined. The ratio for the WT was then average. Lastly, WT 
and experimental samples were all divided by the average WT ratio to determine 
the fold change.   
 For phospho-myosin light chain western blotting, vessels were dissected 
then placed in 5% trichloroacetic acid/acetone solution and immediately placed in 
a -80oC freezer until time to homogenize tissue. On the day of tissue 
homogenization, vessels were taken out of the freezer and allowed to thaw at 
room temperature for 30 minutes. After 30 minutes, vessels were moved into a 
100% acetone solution and sat at room temperature for 30 minutes. Vessels 
were taken out and weighed so that an approximately equal mass of vessel could 
be used. Vessels were homogenized in 50 μL of solution containing: 8M urea, 
20mM tris-base, 22mM glycine, 10mM DTT, 5mM EGTA, 5mM Na2EDTA. 
Samples were spun at 10,000 RPM for 15 minutes at room temperature. The 
supernatant was collected and an equal volume was mixed with Lamelli sample 
buffer and loaded onto a 12% PAGE gel. The gel ran at 125V for two hours. The 
gel was transferred overnight onto a PVDF membrane in buffer containing: 
25mM Tris-base, 192mM glycine, and 20% methanol. The next day, membranes 
were taken out and blocked in 1% BSA in TBS. Phospho-myosin light chain (cell 
signaling technology - cat#: 3674S) was diluted in 1% casein/TBST solution 
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(1:250) and incubated overnight at 4oC. The next day, membranes were 
incubated in Li-Cor secondary antibody (1:15,000) in 1% casein/TBST buffer for 
2 hours. Membranes were visualized on the Li-Cor Odyssey Clx membrane 
scanner and quantified using ImageStudio software version 5.2.5. Immediately 
after membrane visualization, membranes were stripped using Li-Cor NewBlot IR 
stripping buffer according to manufacturer’s protocol. Membranes were blocked 
with 1% BSA/TBS blocking buffer for 1 hour followed by incubation with myosin 
light chain antibody (1:250 - cell signaling technology - cat#: 3672S) in 1% 
casein/TBST solution. Secondary antibody incubation and quantification was 
performed the same as for phospho-myosin light chain. The values were 
represented as a fold change using the same calculations as described above.   
 
Reverse Transcription Polymerase Chain Reaction: Mesenteric arteries and 
RIA were dissected and flash frozen in liquid nitrogen and stored at -80oC. 
Messenger RNA was obtained using the miRNeasy micro kit (Qiagen – cat: 
217084). Equal amounts of RNA were used to generate cDNA using the 
Quantitech cDNA synthesis kit (Qiagen). Taqman primer/probes for Cyp4a12 
(Mm00514494_m1), Myh11 (Mm00443013_m1), Tagln (Mm00441661_g1), 
Acta2 (Mm00725412_s1); Col4a4 (Mm00801574_m1); Col1a1 
(Mm00801666_g1), Ace (Mm00802048_m1), and Tuba1a (Mm00846967_g1) 
were purchased from ThermoFisher. For all reactions, 2 μl cDNA was mixed in 
18 μl of master mix containing: 1 μl of 20X primer/probe, 10 μl 2X Taqman 
advance fast master mix and 7 μl nuclease free water. The thermal profile for 
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qPCR reaction was: 50oC for 2 minutes, 95oC for 20 seconds and 40 cycles of 
95oC for 3 seconds and 60oC for 30 seconds. Relative expression was calculated 
using the 2(-ΔΔCt) method. Ct values were determined using the QuantStudio 3 
RT-PCR machine for all genes of interest. The change in Ct (ΔCt) values were 
determined by taking the difference between the experimental gene from the 
housekeeper gene (Tuba1a). After the determination of the ΔCt, the ΔΔCt value 
was calculated. To do this, the WT ΔCt was averaged. The difference between 
the ΔCt values for each mouse and the average ΔCt values was determined. 
Lastly, 2 was raised to the (-ΔΔCt) to determine the relative expression of the 
gene of interest.     
 
20-HETE Measurements: 20-HETE was quantified by LC-MS/MS-based 
lipidomics. Blood was withdrawn at the end of the experiment by aspiration from 
the inferior vena cava. Briefly, animals were anesthetized with isoflurane, and 
their abdomens were swabbed with 70% alcohol and opened by a midline 
longitudinal incision. Next, the caudal (inferior) vena cava was identified and 
punctured, and blood was drawn into a heparinized syringe. Blood was 
centrifuged at 2,000 rpm for 15 min to separate the plasma. Plasma samples 
were subjected to chloroform-methanol extraction and alkali hydrolysis for 
assessment of free and esterified 20-HETE. Renal preglomerular arteries and 
mesenteric arteries were microdissected and incubated in Kreb’s bicarbonate 
buffer, pH 7, 1 mM NADPH at 37°C for 1 h. Tissue incubations were terminated 
with 2 volumes of cold methanol, internal standards were added, and samples 
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were kept at -80°C. Urine was mixed with two parts of methanol before LC-
MS/MS. Eicosanoids were extracted with solid-phase Strata-X Polymeric 
Reversed Phase 60-mg cartridges (Phenomenex, Torrance, CA). Identification 
and quantification of 20-HETE were performed on a Shimadzu Triple Quadrupole 
Mass Spectrometer LCMS-8050 equipped with a Nexera UHPLC using multiple 
reaction monitoring mode. MS conditions were ionization mode: negative heated 
electrospray (HESI); applied voltage: -4.5 to approximately -3 kV; nebulizer gas: 
3.0 L/min N2; drying gas: 5.0 L/min N2; heating gas: 12.0 L/min air; interface 
temperature: 400°C; desolvation line temperature: 100°C; heat block 
temperature: 500°C; and internal standard: d6 20-HETE. UHPLC conditions were 
as follows: analytical column measures were Zorbax Eclipse Plus C18 RRHD 
(50-mm length x 2.1-mm inner diameter, 1.8 μm); mobile phase A: 95% water-
5% acetonitrile 0.05% acetic acid; mobile phase B: acetonitrile 0.05%; time 
program 40% B (0 min) → 75% B (3 min) → 85% B (7.5 min); flow rate: 0.4 
mL/min; injection volume: 5 μL; column oven temperature: 40°C. Synthetic 
standards were used to obtain standard curves (0.5–500 pg) for each compound. 
These standard curves were used to calculate final concentrations of 20-HETE. 
All solvents were HPLC grade or higher. 
 
Statistics: All values are represented as mean ± SEM. Statistical analysis was 
performed on GraphPad Prism 8 (version 8.4.3). Two-tailed student t-test was 
used to determine significance between two groups. One-way ANOVA with 
Tukey post-hoc test was used to compare differences between three or more 
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means. 2-way ANOVA repeated measures with Sidak’s post hoc test was used 
for phenylephrine, acetylcholine and sodium nitroprusside dose-response 
analysis. For wire and pressure myography experiments, both number of mice 
(N) and number of vessels (n) were reported. Experiments that compared vessel 
reactivity between two genotypes (WT and Myh11-4a12 mice) use N for 
statistical calculations. Experiments that assessed the effectiveness of AAA on 
acetylcholine induced relaxation within one genotype used n for statistical 
calculations. EC50 values from phenylephrine cumulative dose response curves 
were calculated and were compared using one-way ANOVA with Tukey post-hoc 
test. Rmax values from acetylcholine or SNP induced relaxation were compared 
using one-way ANOVA with Tukey post-hoc test. p-values <0.05 were 




Aim 1: To determine if smooth muscle-specific overexpression of Cyp4a12-
20-HETE synthase causes hypertension and vascular dysfunction. 
 
Myh11-Cre(+/-)-Cyp4a12-Flox(+/wt) (Myh11-4a12) had significantly elevated 
Cyp4a12 levels in vessels that resulted in elevated 20-HETE 
Myh11-4a12 mice had a significant increase of Cyp4a12 mRNA 
expression in resistant vessels (mesenteric arteries: 8.62 ± 1.26 vs 1.44 ± 0.30; 
RIA: 5.95 vs 1.12, relative expression to Tuba1a, p<0.0001) compared to WT 
(Figure 1A and 1B). The increase in expression was not observed in liver 
(Figure 1C: 1.56 ± 0.54 vs 1.91 ± 0.37 relative expression to Tuba1a). The 
overexpression of mRNA translated to increased Cyp4a protein levels when 
comparing mesenteric arteries of Myh11-4a12 mice to WT (Figure 2A: 1.95 ± 
0.21 vs 1.00 ± 0.21 Cyp4a/β-actin fold expression, p<0.05). Increases in Cyp4a 
protein expression were not observed in livers (Figure 2B: 1.00 ± 0.15 vs 1.00 ± 
0.15, Cyp4A/β-actin fold change). Furthermore, elevated Cyp4a12 was 
associated with increased 20-HETE levels in mesenteric arteries (3334 ± 891 
pg/mg protein vs 545 ± 197 pg/mg protein, p<0.05), RIA (1895 ± 376 pg/mg 
protein vs 242 ± 63 pg/mg protein, p<0.05), and plasma (391 ± 52 pg/mL vs 242 
± 18 pg/mL, p=0.05) without any changes in urinary levels (117 ± 29 pg/mL vs 




Myh11-4a12 mice are hypertensive and have impaired vascular function.  
Systolic blood pressure (SBP) measured at 8-10-weeks of age was 
significantly higher in Myh11-Cyp4a12 mice compared to WT mice (Figure 5A: 
144 ± 2 vs 130 ± 1 mmHg, p<0.0001). Isolated RIA from Myh11-4a12 mice 
displayed impaired acetylcholine-induced relaxation after precontraction with 
phenylephrine compared to RIA from WT mice (Figure 5B: Maximal relaxation: 
47% ± 6.9 vs. 80% ± 4.3 p<0.001). Renal interlobar arteries from Myh11-4a12 
mice given a NO donor (SNP) were able to relax to a degree similar to WT 
(Figure 5C: Maximal relaxation: 85% ± 4.0 vs 80% ± 9.0) Measurements of 
vessel wall thickness were taken to assess 20-HETE’s effects on vascular 
remodeling. Myh11-4a12 mice had an increase media:lumen ratio compared to 
WT (Figure 6A: 0.332 ± 0.027 vs 0.164 ± 0.010, p<0.0001, student t-test). Media 
thickness (Figure 6B: 25.70 ± 1.22 μm vs 15.00 ± 0.71 μm, *p<0.05) and media 
cross-sectional area (Figure 6C: 15718 ± 1496 μm2 vs 10407 ± 660 μm2, 
*p<0.05) were also elevated in Myh11-4a12 mice compared to WT mice.  
 
Markers of smooth muscle cell contraction and NO signaling were altered 
in Myh11-4a12 mice.  
20-HETE has been documented to have multiple actions on vessels to 
increased contractility and impaired relaxation. Phosphorylation of myosin light 
chain at serine 19 was used as a marker for increased cellular signaling for 
VSMC contraction. Mesenteric arteries from Myh11-4a12 mice had a 40% 
increase in phosphorylation of myosin light chain compared to WT mice (Figure 
7: 1.40 ± 0.13 vs 1.00 ± 0.08 Ser19 p-MLC/total-MLC fold change, p<0.05). 
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Phosphorylation of eNOS was used as a marker for EC cell function and 
enhanced relaxation. In aortas of Myh11-4a12 mice, there were reductions in 
both phosphorylated and total eNOS expression that was significantly lower than 
WT mice (Figure 8: 0.43 ±  0.19 vs 1.23 ±  0.26 Serine 1177/β-tubulin fold 
change, *p<0.05 and 0.57 ± 0.14 vs 1.00 ±  0.08 total eNOS/ β-tubulin fold 
change).    
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Figure 1: Myh11-4a12 mice display overexpression of Cyp4a12 in vessels.  
 
RT-PCR result: A) mesenteric artery (N=14/group; ***<0.001 student t-test), B) 




































































































































Figure 2: Myh11-4a12 mice have elevated Cyp4a protein in vessels.  
 
A) Mesenteric artery (N=4/group, *p<0.05 compared to wild type, student t-test) 
but no difference was observed in B) liver (N=8/group, student t-test). 
  
 
Myh11-4a12 Wild Type 

































































































Figure 3: Myh11-4a12 mice display elevated 20-HETE. 
 
A) Mesenteric arteries (N=5 WT, n=6 Myh11-4a12), B) RIA (N=3/group), C) 
Plasma (N=4 WT, N=6 Myh11-4a12) but not in D) Urine (N=5/group). Mean ± 




























































































































Figure 4: Mice with smooth muscle-specific overexpression of Cyp4a12 are 
hypertensive.  
 
Baseline systolic blood pressure measurement. N=22 Wild type; N=27 Myh11-




































































Figure 5: Mice with smooth muscle-specific overexpression of Cyp4a12 
have impaired relaxation.  
 
A) Acetylcholine-induced relaxation after phenylephrine precontraction. Wild type 
N=13 mice, n=26 vessels and Myh11-4a12 N=15 mice, n=28 vessels. 
***p<0.001, t-test. B) Administration of SNP improved relaxation of vessels with 
overproduction of 20-HETE. Wild Type: n=3 mice; Myh11-4a12: n=4 mice. t-test. 
Means ± SEM,  
 
  WT 
Myh11-
4a12 
Rmax 80% 47%**** 
  WT 
Myh11-
4a12 
Rmax 80% 85% 



















































































































Figure 6: Renal interlobar artery measurements of vascular remodeling are 
elevated in Myh11-4a12 mice.  
 
A) Media:lumen ratio, B) Media thickness, and C) Media cross-sectional area. 
Wild type N=12 mice, n=24 vessels, Myh11-4a12 N=14 mice, n=28 vessels; 





























































































Figure 7: Baseline expression of myosin light chain phosphorylation at 
serine 19 in mesenteric arteries were elevated in Myh11-4a12 mice.  
 















































































































Figure 8: Baseline expression of phosphorylated and total eNOS was 
reduced in aortas of Myh11-4a12 mice.  
 
A) Serine 1177 phosphorylated eNOS to β-tubulin ration and B) total eNOS to β-



















































































Aim 2: To determine if the vascular pathology in Myh11-4a12 mice is 20-
HETE-dependent. 
 
Administration of AAA decreased systolic blood pressure and improved 
vascular function in mice with smooth muscle-specific Cyp4a12 
overexpression. 
Myh11-4a12 mice were hypertensive compared to WT on day 0 (Figure 9: 
Myh11-4a12 ((combine): 146 ± 3 mmHg vs WT – vehicle: 132 ± 3 mmHg, 
p<0.001, student t-test). Twelve days of AAA treatment normalized SBP to WT 
levels with values starting to decrease at day 4 (Day 12: Myh11-4a12 – AAA 126 
± 1 vs 129 ± 1 mmHg). Wild type mice on AAA had no changes in SBP 
compared to WT mice on vehicle (data not shown). Administration of AAA 
appeared to have no effect on 20-HETE levels in the plasma. Myh11-4a12 mice 
had elevated 20-HETE levels compared to WT (Figure 10: 298 ± 35 vs 157 ± 23 
pg/mL plasma, p<0.05) however, Myh11-4a12 mice on AAA (298 ± 58 pg/mL 
plasma) had a similar value compared to Myh11-4a12 mice on vehicle.  
Fluid balance and urinary sodium excretion was also assessed to 
determine if the blood pressure lowering effect of AAA was also due to changes 
in the renal handling of salt and fluid. Mean values for water consumption 
appeared similar between the three groups (Figure 11A: Wild type – vehicle: 
0.38 vs Myh11-4a12 – vehicle: 0.38 vs Myh11-4a12 – AAA 0.37  mL/gram body 
weight/24 hours). Urine volume was similar between WT and Myh11-4a12 mice 
on vehicle (Figure 11B: 52.0 vs 55.6 μL/gram body weight/24 hours). Urine 
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excretion appeared to increase in Myh11-4a12 mice on AAA (75.6 μL/gram body 
weight/24 hours), however, no conclusion was made due to the small sample 
size. Similar trends were observed when measuring urinary sodium excretion. 
Average values for urinary sodium excretion were similar between Myh11-4a12 
and WT mice on vehicle (6.91 μmole/gram body weight vs 7.71 μmole/gram body 
weight/24 hours). While there was an upward trend in sodium excretion in 
Myh11-4a12 mice on AAA, no conclusions could be determined due to the small 
sample size (11.35 μmole/gram body weight/24 hours).   
After day 12, mice were sacrificed and RIA were isolated for wire 
myography. RIA from Myh11-4a12 mice displayed impaired acetylcholine-
induced relaxation compared to WT mice (Rmax: 67% ± 5 vs 90% ± 2, 
P<0.0001). Myh11-4a12 mice on AAA had improved acetylcholine relaxation with 
values similar to WT (Rmax: 96% ± 1) (Figure 12A). Changes in phenylephrine-
induced contractions were also observed. RIA from Myh11-4a12 mice were more 
sensitive to phenylephrine-induced contraction compared to WT (EC50: 1.63 x 10-
7 μM vs. 5.00 x 10-7 μM, p<0.0001). The sensitivity of phenylephrine for Myh11-
4a12 mice on AAA (EC50: 4.22 x 10-7 μM) was not different compared to WT 
(Figure 12B). 
Ex vivo experiments were performed to assess the direct actions of AAA 
in RIA to promote relaxation. Both WT and Myh11-4a12 vessels were treated 
with vehicle first followed by 10 μM AAA. Wild type vessels had no apparent 
difference in the ability to relax after acetylcholine-induced relaxation (Figure 
13A). On the other hand, Myh11-4a12 mice displayed improved relaxation 
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response after acetylcholine administration. Myh11-4a12 vessels had a maximal 
% relaxation of 40 ± 6% after vehicle treatment. AAA pretreatment resulted in 
improved relaxation (63 ± 7%, p<0.05) (Figure 13B). Comparisons were made 
between the four groups at the highest does of acetylcholine administration. 
Myh11-4a12 vessels on vehicle had significantly impaired relaxation response 
compared to WT either on vehicle or AAA (Figure 13B: 40 ± 6% vs. 67 ± 6 WT – 
vehicle and 64 ± 6% WT – AAA, p<0.05). AAA was able to significantly improve 
the ability of the vessels to relax in Myh11-4a12 mice. Myh11-4a12 vessels after 
AAA had similar relaxation values compared to WT on vehicle or AAA (Figure 
13C: 63 ± 4%)  
 
AAA administration improved media:lumen ratio but did not affect media 
thickness or cross-sectional area of RIA 
Renal interlobar arteries from Myh11-4a12 mice had a media:lumen ratio 
that was significantly higher than WT (Figure 14A: 0.277 ± 0.025 vs 0.163 ± 
0.006, P<0.0001). RIA from AAA-treated Myh11-4a12 mice showed a reduction 
in media:lumen ratio (0.129 ± 0.013, p<0.05) when compared to Myh11-4a12 on 
vehicle (Figure 14A). Analysis of media wall thickness and media cross-sectional 
area show that AAA did not have an effect on vessel wall thickness. Both Myh11-
4a12 mice either on vehicle or AAA had a thicker media (Figure 14B: 23.85 ± 
2.25 μm and 20.72 ± 1.37 μm vs 15.86 ± 0.83 μm, p<0.0001 WT - vehicle vs 
Myh11-4a12 - vehicle and p<0.05 WT - vehicle vs Myh11-4a12 – AAA) and 
cross-sectional area (Figure 14C: 15114 ± 1871 μm2 and 14268 ± 1259 μm2 vs 
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10560 ± 641 μm2, p<0.05 WT - vehicle vs Myh11-4a12 - vehicle and p=0.08 WT - 
vehicle vs Myh11-4a12 – AAA) compared to WT. Western blot analysis for 
myosin heavy chain 11, a marker of vascular smooth muscle cell differentiation, 
is in line with these results. Myh11-4a12 mice either on vehicle or AAA appeared 
to have higher myosin heavy chain expression compared to WT on vehicle 
(Figure 14D: 3.10 ± 0.98 Myh11/β-tubulin fold change and 3.25 ± 0.72 Myh11/β-
tubulin fold change vs 1.00 ± 0.10 Myh11/β-tubulin fold change).   
 
Markers of VSMC differentiation were elevated in Myh11-4a12 mice.  
At baseline, the vessel wall was thicker in Myh11-4a12 mice compared to 
WT mice. This may be due to 20-HETE’s ability to cause VSMC proliferation 
which increases the number of mature cells within the vessel wall. To determine 
this, markers of VSMC differentiation [Myh11, Sm22a, Acta2] were measured in 
renal interlobar arteries (Figure 15). Myh11 (RIA: 1.67 ± 0.22 vs 1.18 ± 0.22, 
relative expression to tuba1a), Tagln (2.13 ± 0.25 vs 1.17 ± 0.26 relative 
expression to tuba1a, p<0.05 t-test), and Acta2 (RIA: 1.94 ± 0.23 vs 1.14 ± 0.20, 
relative expression tuba1a, p<0.05 t-test) mRNA expression were all elevated 






No differences in collagen expression were observed between Myh11-4a12 
and wild type mice.  
20-HETE has been documented to promote increases in collagen 
synthesis in rats (Soler et al., 2018). Messenger RNA of Collagen I and Collagen 
IV were assessed to determine if increase in collagen synthesis was occurring 
which may contribute to the stiffening of the vessels and increase in blood 
pressure. Collagen I (0.76 ± 0.28 vs 1.25 ± 0.25, relative expression to Tuba1a) 
and collagen IV (1.12 ± 0.29 vs 1.25 ± 0.30, relative expression to Tuba1a) were 





























Figure 9: Administration of a 20-HETE receptor antagonist (AAA) was able 
to lower blood pressure after 12 days.  
 
A) Wild Type or Myh11-4a12 mice underwent either vehicle treatment or AAA 
(10mg/kg/day) treatment for 12 days. N=12 Wild type – vehicle; N=11 Myh11-
4a12 – vehicle; N=14 Myh11-4a12 – AAA. *p<0.05 of Myh11-4a12 compared to 
wild type. #p<0.05 Myh11-4a12 – vehicle to Myh11-4a12 – AAA. 2-way ANOVA 
with Tukey post-hoc test.  
  


































































Figure 10: Plasma 20-HETE levels were unchanged after 12-day AAA 
treatment.  
 
Wild type - Vehicle N=13, Myh11-4a12 - Vehicle N=15, Myh11-4a12 – AAA 































































































Figure 11: Urine volume and sodium excretion in WT and Myh11-4a12 mice 
treated with and without AAA.  
 
A) water consumption, B) urine volume, C) urinary sodium. Wild type – vehicle 




























































































































































































Figure 12: Vascular activity was improved after 12 days of AAA treatment. 
 
 A) Dose response acetylcholine induced relaxation on RIA after 12 days of AAA 
treatment. Wild Type – vehicle N=7 mice, n=14 vessels; Myh11-4a12 – vehicle 
N=7 mice, n=14 vessels; Myh11-4a12 – AAA N=7 mice, n=14 vessels. 
***p<0.001 Wild Type - vehicle vs Myh11-4a12 -vehicle; ####p<0.0001 Myh11-
4a12 - vehicle vs Myh11-4a12 – AAA. One-way ANOVA. B) Dose response 
phenylephrine induced contraction on RIA after 12 days of treatment. Wild Type 
– Vehicle N=7 mice, n=14 vessels; Myh11-4a12 – vehicle N=9 mice, n=18 
vessels; Myh11-4a12 – AAA N=6 mice, n=12 vessels. ***p<0.001, ##p<0.01 One-
way ANOVA  
 






Rmax 90% 67%*** 94%#### 
 






EC50 (μM) 5.00x10-7 1.63x10-7*** 4.22x10-7## 









































































































Figure 13: Myh11-4a12 mice had improved relaxation with AAA treatment 
ex vivo.  
 
A) Wild type N=3 mice, n=9 vessels. B) Myh11-4a12 N=6 mice, n=17 vessels 
vehicle and n=16 vessels AAA treatment. *p<0.05 2-way ANOVA. C) 
comparisons of all treatments at 10-4M acetylcholine. P<0.05 one-way ANOVA.  
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Figure 14: Myh11-4a12 mice have an elevated media:lumen ratio that was 
reduced with AAA treatment, however, AAA did not reduce the thickness of 
the vessel.  
 
Renal interlobar arteries underwent pressurized myography and the inner and 
outer diameters were measured. A) media:lumen ratio; B) media thickness; C) 
media cross-sectional area (CSA). Wild type – vehicle N=9 mice, n=18 vessels 
Myh11-4a12 – vehicle N=7 mice, n=14 vessels, Myh11-4a12 – AAA N=8 mice, 
n=16 vessels. Mean ± SEM one-way ANOVA *p<0.05, **p<0.01, ***p<0.001. D) 
Western blot analysis for smooth muscle-specific myosin heavy in mesenteric 
arteries. N=5 wild type - vehicle, N=4 Myh11-4a12 – vehicle, N=5 Myh11-4a12 – 








































































































































































































































Figure 15: Increases in markers of VSMC differentiation were observed in 
RIA of Myh11-4a12 mice.  
 
A) Myh11 (N=6/group B) Tagln (wild type: N=7; Myh11-4a12: N=6); C) Acta2 


















































































































Figure 16: No differences in collagen expression were observed between 
Myh11-4a12 and wild type mice.  
 
A) Collagen I and B) Collagen IV. Wild Type: N=11; Myh11-4a12: N=8. Means ± 


























































Aim 3: To explore cellular mechanisms underlying the increased 
contractility of arteries from mice with smooth muscle-specific 
overexpression of Cyp4a12. 
 
No changes were observed in ACE mRNA expression between wild type 
and Myh11-4a12 mice.  
ACE expression has been shown to increase with elevated 20-HETE. 
Increases in ACE result in increases in angiotensin II which may have a direct 
action on vessels to cause contraction. ACE is primarily expressed in the 
endothelium, however, there is also ACE expression in the VSMC (Fishel et al., 
1995). After measuring Ace mRNA in mesenteric arteries, there was no 
difference between Myh11-4a12 and WT mice (Figure 17: 1.36 ± 0.26 vs 1.03 ± 
0.126, relative expression to tuba1a) 
 
Myh11-4a12 mice appeared to have reductions in eNOS activation which 
was increased with AAA treatment.  
Myh11-4a12 mice with elevated 20-HETE have impaired relaxation to 
acetylcholine, and administration of a 20-HETE receptor antagonist improves the 
relaxation of the vessel to a level similar to wild type. Furthermore, administration 
of a NO donor allowed the vessel from Myh11-4a12 mice to relax to a degree 
similar to WT. This suggests that vessels from Myh11-4a12 mice have an 
impairment in NO bioavailability. The inhibition of eNOS activation is one 
possible reason for this impairment. Activation of eNOS was measured by 
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phosphorylation of eNOS at Serine 1177 via western blotting. Myh11-4a12 mice 
appeared to have reductions in Serine 1177 phosphorylation compared to wild 
type in aorta (Figure 18A: 0.43 ± 0.19 vs 1.23 ± 0.26, Ser1177 p-eNOS/β-tubulin 
fold change). Myh11-4a12 mice also appeared to have lower total eNOS 
expression compared to WT (Figure 18B: 0.57 ± 0.14 vs 1.00 ± 0.08 total 
eNOS/β-tubulin fold change). AAA treatment appeared to increase 
phosphorylation (1.42 ± 0.58, Ser1177 p-eNOS/β-tubulin fold change) and total 
eNOS (1.20 ± 0.58, total eNOS/β-tubulin fold change) levels of Myh11-4a12 mice 
to a value greater than WT. Vasodilator-stimulated phosphoprotein (VASP) 
phosphorylation at Serine 239 was also measured because it is an indicator that 
NO from the EC is able to reach the VSMC. Myh11-4a12 mice had reductions in 
VASP phosphorylation compared to WT (0.61 ± 0.09 vs 1.00 ± 0.04, Ser239 p-
VASP/total VASP fold change, p<0.01) which was unchanged when Myh11-4a12 
mice were given AAA (Figure 18C: 0.63 ± 0.07, Ser239 p-VASP/total VASP fold 
change). In mesenteric arteries, changes in phosphorylation of eNOS were also 
observed. Myh11-4a12 mice appeared to have reduced eNOS phosphorylation 
(Figure 19: 0.57 ± 0.06 vs 1.00 ± 0.23 Ser1177 p-eNOS/total eNOS, p=0.15) and 
Myh11-4a12 mice that were given AAA had increase phosphorylated eNOS 
levels (1.07 ± 0.08 p-eNOS/total eNOS, p=0.20). Unlike aortas, there were no 





Administration of the 20-HETE receptor antagonist was able to reduce 
phosphorylation of myosin light chain.  
20-HETE’s ability to change the sensitivity of RIA to phenylephrine 
suggests that 20-HETE can mediate actions to cause changes in 
phosphorylation state of myosin light chain. When probing for the 
phosphorylation of Serine 19 on the regulatory subunit of myosin light chain, 
there was approximately a 60% increase in the Myh11-4a12 group compared to 
wild type (1.60 ± 0.23 vs 1.00 ± 0.06 Ser19 p-MLC/total MLC fold change, p<0.05 
one-way ANOVA). Myh11-4a12 mice treated with AAA had reduced phospho-
myosin light chain levels (0.94 ± 0.11, Ser19 p-MLC/total MLC fold change, 
p<0.05 vs Myh11-4a12 – vehicle, one-way ANOVA) that were similar to wild type 
(Figure 20).  
 
20-HETE was able to increase Rho-kinase activity which was attenuated 
with AAA.  
Upstream of myosin light chain is Rho-kinase (ROCK). RhoA-GTP 
activates ROCK which causes the phosphorylation and inhibition of myosin light 
chain phosphatase. Inhibition of myosin light chain phosphatase allows for the 
phosphate group on myosin light chain to stay on so it remains in a contractile 
state. ROCK1 protein was measured in RIA and there was a 60% increase in 
Myh11-4a12 mice compared to wild type (Figure 21: 1.60 ± 0.21 vs 1.00 ± 0.18, 
p<0.05). AAA treatment did not affect the protein expression of ROCK1 (data not 
shown). Although AAA was not able to decrease ROCK1 expression, it is 
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possible that AAA can change activity of ROCK. To assess this, WT RIAs were 
used and pressure myography was performed to asses AAA and ROCK inhibitor, 
Y-27632, on 20-HETE-induced changes in myogenic response. Treating RIA with 
20-HETE produced a downward shift in the absolute ID and the normalized ID 
curves (Figure 22 A&B). Co-treatment with 20-HETE plus AAA or ROCK 
inhibitor (Y-27632) shifted the curve upward overlapping the vehicle treated 
vessels. Lastly, combined treatment of 20-HETE with AAA and ROCK inhibitor 
did not result in any further upward shifts in either the absolute ID or normalized 
ID curves. The most significant changes happened at pressure of 80 mmHg and 
100 mmHg (Figure 23). At 80 mmHg, 20-HETE reduced the absolute ID (106 ± 
2.5 μm vs 124 ± 2.6 μm, p<0.01) and the normalized ID (42 ± 0.86 % vs 48 ± 
0.79%, p<0.001) significantly compared to WT. Co-treatment with 20-HETE plus 
AAA (absolute ID: 124 ± 2 μm, p<0.001; normalized ID: 48.8 ± 0.89%, p<0.0001) 
or Y-27632 (absolute ID: 126 ± 3 μm, p<0.001; normalized ID: 49 ± 1.2%, 
p<0.0001) increase the absolute ID and the normalized ID significantly compared 
to 20-HETE only. Treatment of RIA with 20-HETE plus AAA and Y-27632 did not 
produce any further increase in absolute ID (113 ± 4.6 μm, p<0.001 vs 20-HETE 
treatment) or normalized ID (49 ± 1.4%, p<0.0001 vs 20-HETE treatment). 
Similar results were observed at 100 mmHg. Administration of 20-HETE in the 
bath reduced the absolute ID (90 ± 3.3 vs 106 ± 3.2 μm, p<0.05) and the 
normalized ID (33 ± 1.1 vs 39 ± 0.94%, p<0.01) compared to vehicle treated. 
Adding either AAA (Absolute ID: 109 ± 3.4 μm, p<0.01; normalized ID: 41 ± 
0.97%, p<0.001) or Y-27632 (Absolute ID: 108 ± 3.7, p<0.01; normalized ID: 40 ± 
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1.1%, p<0.001 ) blunted the increased myogenic response due to 20-HETE. 
Treatment with 20-HETE, AAA and Y-27632 did not further increase the absolute 






























Figure 17: No differences in ACE mRNA expression were observed 
between Myh11-4a12 and wild type mice in mesenteric arteries.  
 


































































































































Figure 18: Western blot analysis of eNOS and VASP phosphorylation in 
aorta. 
 
A) Serine 1177 phospho-eNOS/β-tubulin and B) total eNOS/ β-tubulin. N=6 wild 
type – vehicle and Myh11-4a12 – vehicle; N=7 Myh11-4a12 – AAA, *p<0.05 one-
way ANOVA. C) Serine 239 phospho-VASP/total VASP. N=5 wild type – vehicle 
N=4 Myh11-4a12 – vehicle and Myh11-4a12 – AAA, **p<0.01, One-way ANOVA.  
B) A) 

















































































































































































Figure 19: Phosphorylation of eNOS at serine 1177 after 12 days of AAA 
treatment in mesenteric arteries of Myh11-4a12 mice.  
 






































































































Figure 20: Myh11-4a12 mice have elevated phosphorylation of myosin light 
chain that was reduced with 12 day AAA treatment.  
 
A) Western blot analysis of Serine 19 phospho-myosin light chain expression in 
mesenteric arteries after 12-day AAA treatment (N=7 Wild Type – Vehicle and 















































































































Figure 21: ROCK1 protein expression was elevated in Myh11-4a12 mice.  
 










































Figure 22: Addition of AAA or Y-27632 prevented 20-HETE-mediated 
increase in myogenic tone of RIA from WT mice.  
 
 A) absolute internal diameter (ID) and B) percent myogenic tone. Vehicle, 20-
HETE only, 20-HETE + AAA, 20-HETE + Y-27632 – N= 6 mice, n=12 vessels; 
20-HETE + AAA + Y-27632 – N = 4 mice, n=8 vessels.  
 
Vehicle 20-HETE 20-HETE + AAA
20-HETE + Y-27632 20-HETE + AAA + 
Y-27632























































































Figure 23: Absolute internal diameter (ID) and percent myogenic tone 
values of WT RIA at 80mmHg and 100mmHg.  
 
 A) absolute and B) normalized ID at 80 mmHg and C) absolute and D) 
normalized ID at 100 mmHg. Vehicle, 20-HETE only, 20-HETE + AAA, 20-HETE 
+ Y-27632 – N = 6 mice, n=12 vessels; 20-HETE + AAA + Y-27632 – N = 4 mice, 
n=8 vessels. *p<0.05, **p<0.01, ***p<0.001 vs vehicle treated. ##p<0.01, 







































































































































































































































































The present study provides evidence to show the actions of 20-HETE 
within the vascular smooth muscle cell to promote hypertension and vascular 
dysfunction. The main findings of this study include: 1) vascular smooth muscle-
specific overexpression of Cyp4a12 and increased vascular production of 20-
HETE was sufficient to promote increases in blood pressure and impairment in 
vascular function; 2) treatment with a novel, water-soluble 20-HETE receptor 
antagonist (AAA) reversed the pathology associated with 20-HETE 
overproduction; 3) elevated 20-HETE changes signaling within the VSMC and 
EC which was reversed with AAA treatment. The signaling mechanisms that 
were assessed were Rho-kinase-mediated myosin light chain phosphorylation 
and NO signaling.  
The actions of 20-HETE within the vasculature have been extensively 
shown in animal models with global overproduction of 20-HETE. These models 
have consistently shown that increased 20-HETE within the vasculature 
promotes hypertension and vascular dysfunction. The limitation of using global 
models of 20-HETE production is the difficulty to dissect how 20-HETE within 
specific cell types contributes to changes in vascular function. The utilization of 
animal models with site-specific expression of 20-HETE can better show the 
mechanism in which 20-HETE produces changes in vascular function with a 
certain cell type.  
In this study, the cre/flox system was utilized to target Cyp4a12 
overexpression to the smooth muscle cell. The reason for this approach of 
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Cyp4a12 overexpression was to overproduce 20-HETE in the primary site of 
synthesis (Harder et al., 1994; Gebremedhin et al., 1998). 20-HETE has been 
shown to produce effects within the VSMC to change blood pressure and 
vascular function in vitro and in models of global overproduction of 20-HETE. 
This is the first time that Cyp4a12 was endogenously overexpressed in the 
VSMC to produce 20-HETE in a mouse.    
The mouse model that was used in the present study was appropriate to 
assess the consequence of 20-HETE overproduction generated by the VSMC. 
The cre/lox system was used to target Cyp4a12 production, specifically in the 
VSMC. The Cyp4a12-flox gene was constructed to have the regulatory unit of the 
gene flanked with the LoxP site. In the presence of cre-recombinase, the 
regulatory unit of the gene was removed to allow for unregulated production of 
Cyp4a12 (Gilani et al., 2020). Cyp4a12-flox expression was targeted to the 
VSMC by site-specific cre-recombinase production under the control of the 
smooth muscle-specific myosin heavy chain promoter (Myh11-Cre) (Xin et al., 
2002). This was evident when probing for Cyp4a12 expression at the mRNA and 
protein level. In mesenteric and RIAs, there was significant increase in Cyp4a12 
mRNA expression compared to WT mice. There was also a significant increase 
in Cyp4a protein levels in the mesenteric artery compared to WT mice. These 
changes were not observed in the liver.  
The result of the VSMC-specific overexpression of Cyp4a12 was elevated 
20-HETE levels. Elevated 20-HETE levels were observed in mesenteric arteries, 
RIA, and plasma; however, no change in 20-HETE was observed in urine. This 
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gives evidence that 20-HETE production is directed to the vessels, but the 20-
HETE produced in the vessels can be found in circulating stores. Mice with 
elevated 20-HETE also had elevated systolic blood pressure and impairments in 
acetylcholine-induced relaxation. When performing western blots to reinforce the 
results from the ex vivo experiments in vessels, changes in eNOS expression in 
the aorta and serine 19 phospho-myosin light chain expression were also 
observed. Altogether, the results demonstrate that VSMC-specific Cyp4a12 
expression results in elevated 20-HETE and impairments in vascular activity, 
which contribute to changes in systolic blood pressure.  
Global overexpression models of 20-HETE are shown to cause increases 
in blood pressure and impairment in vascular reactivity. One model of global 
overproduction of 20-HETE is the Cyp4a14-/--mouse. The Cyp4a14-/--mouse has 
global overexpression of Cyp4a12, the main 20-HETE-producing enzyme in 
mice, and its expression is driven by the androgen promoter. This mouse model 
resulted in elevated 20-HETE levels in male mice but not in female (Holla et al., 
2001). Increase in blood pressure and impairment in vascular reactivity are 
associated with elevated 20-HETE in these mice. In a report by Pandey et. al. 
(2017), they showed that Cyp4a14-/--mice had increases in blood pressure and 
changes in phenylephrine-induced contraction that were reversed with a 20-
HETE antagonist (Pandey et al., 2017).  
Another model of constitutive 20-HETE overproduction was the Tie2-
CYP4F2-Tr mouse model. CYP4F2 is a major 20-HETE-producing enzyme in 
humans with CYP4F2 activity associated with hypertension (Ward et al., 2008). 
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The investigators were interested in CYP4F2 expression within the vessels which 
may contribute to 20-HETE-dependent vascular pathology. In their report, they 
generated a mouse model that had CYP4F2 expression controlled by the EC-
specific Tie-2 promoter (Cheng et al., 2014). These mice exhibit elevated 
CYP4F2 expression with corresponding 20-HETE elevation, specifically in the 
EC. There were no differences in blood pressure and acetylcholine-induced 
relaxation but there were differences in phenylephrine-induced contraction. 
Furthermore, the investigators showed a pro-angiogenic phenotype in the Tie2-
CYP4F2-Tr mouse. This suggests that EC-specific CYP4F2 expression primarily 
drives changes in angiogenesis and changes in vascular function may be 
secondary to the actions of 20-HETE in the EC.   
Each mouse model has its utilities when studying the mechanism of 
vascular impairment dependent on 20-HETE. The Cyp4a14-/- mouse model is a 
good model for reliable, global 20-HETE overproduction (CC Wu et al., 2013; 
Ding et al., 2013; Pandey et al., 2017). It has been used to identify the ability of 
20-HETE to impair vascular function (Ding et al., 2013; Pandey et al., 2017). 
However, the limitation of using the Cyp4a14-/- mouse is its inability to identify 20-
HETE’s action within specific tissue types to promote vascular impairments. The 
Tie2-CYP4F2-Tr is one model of 20-HETE overproduction within the EC. It has 
been documented that this mouse line was not able to produce any changes in 
blood pressure, but was able to promote a pro-angiogenic phenotype (Cheng et 
al., 2014). Thus, there are limitations of using the Tie2-CYP4F2-Tr mouse when 
it comes to assessing mechanisms of blood pressure. In the present study, the 
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Myh11-4a12 mouse showed elevated 20-HETE levels in vessels which were 
associated with increases in blood pressure and impairments in vascular 
function. Thus, the different phenotypes observed with different mouse models of 
20-HETE overproduction are influenced by the site of 20-HETE overproduction.  
AAA was used to assess the dependence of 20-HETE on blood pressure, 
vascular reactivity and remodeling. In the present study, 12 days of AAA 
treatment was sufficient to lower blood pressure to a value similar to the wild type 
controls. Phenylephrine-induced contraction and acetylcholine-induced relaxation 
both were improved after 12 days of AAA treatment. Ex vivo experiments to 
assess AAA direct action on RIA showed that mice with Cyp4a12 overexpression 
had improved relaxation compared to untreated mice, and no changes were 
observed in WT mice. Interestingly, when assessing vascular remodeling, only 
the media:lumen ratio was affected by AAA. Media thickness or cross-sectional 
area was unchanged after AAA treatment.   
AAA has been documented as a 20-HETE receptor antagonist capable of 
lowering blood pressure in models of 20-HETE-dependent hypertension 
(Sedláková et al., 2018). In a report by Sedlákova et. al. (2018), they used the 
Cyp1a1-Ren-2 rat model that has overproduction of 20-HETE and angiotensin II 
(Sedláková et al., 2018). The investigators administered AAA for 12 days in the 
drinking water and they showed a significant reduction in systolic blood pressure 
compared to untreated hypertensive rats. The reduction in systolic blood 
pressure was accompanied by improved renal function. The spontaneous 
hypertensive rat is another model of hypertension that is 20-HETE-dependent. 
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Two reports showed that AAA treatment in the spontaneous hypertensive rat 
lowers blood pressure and improves renal function. In one report, AAA was 
administered IV and reductions in mean arterial blood pressure were observed 
(Walkowska et al., 2021). The changes in mean arterial blood pressure were 
accompanied by improvements in renal blood flow. Another report using the 
spontaneous hypertensive rat administered AAA in the drinking water rather than 
IV. The authors reported reductions in systolic blood pressure after 36 days of 
AAA treatment, although the reduction was not significant compared to the 
hypertensive controls (Gawrys et al., 2020). The reduction in systolic blood 
pressure was accompanied by improvements in renal function as assessed by 
reductions in albuminuria.  
Fluid balance and sodium excretion was measured to determine if the 
blood pressure lowing effect of AAA had a renal component. Previous reports 
suggest that AAA was able to improve renal parameters which contributed to the 
lowering of blood pressure (Sedláková et al., 2018; Gawrys et al., 2020; 
Walkowska et al., 2021). The goal of this experiment was to examine if AAA can 
affect sodium excretion and fluid balance in Myh11-4a12 mice. The Myh11-4a12 
mice displayed no differences in 20-HETE levels in the urine compared to WT 
mice. Urine volume and sodium excretion were similar between WT and Myh11-
4a12 mice. AAA appeared to increase urine volume and sodium excretion in 
Myh11-4a12 mice compared to Myh11-4a12 mice on vehicle. Due to the similar 
values between WT and Myh11-4a12 mice and the small sample size, no 
conclusions were made surrounding AAA and its effects across the kidney.  
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20-HETE within the kidney display effects to promote changes in blood 
pressure through regulation of salt and fluid handling. In vivo experiments have 
demonstrated 20-HETE’s pro- and anti-hypertensive role in the kidney. In 
experiments that manipulate 20-HETE levels acutely, 20-HETE was shown to be 
antihypertensive. Elevated 20-HETE within the kidney inhibits Na+/K+--ATPase 
(Schwartzman et al., 1985; Nowicki et al., 1997), and NKCC2 (Amlal et al., 1998; 
Ito and Roman, 1999). These actions facilitate the reduction of blood pressure 
through increased salt and fluid excretion. On the other hand, 20-HETE has been 
shown to elevate blood pressure through changes in renal blood flow and sodium 
reabsorption in animal models with 20-HETE-dependent hypertension. Animal 
models of 20-HETE-dependent hypertension include: 1) Cyp4a14-/- (Quigley et 
al., 2009; Pandey et al., 2017), 2) Cyp4a11 transgenic mouse (Savas et al., 
2016), 3) proximal tubule targeted Cyp4a12 (PT-4a12) mouse (Gilani et al., 
2020). The Cyp4a14-/- mouse display reductions in renal blood flow (Pandey et 
al., 2017) and increase in activity of the sodium hydrogen exchanger (NHE3) 
(Quigley et al., 2009), both which promote sodium and fluid retention. In both the 
Cyp4a11 transgenic and PT-4a12 mouse, 20-HETE has been shown to increase 
expression of serum- and glucocorticoid-inducible kinase-1 (SGK-1) and increase 
activity of the sodium chloride exchanger (NCC) to increase sodium and fluid 
reabsorption (Savas et al., 2016; Gilani et al., 2020).  
The differences in the actions of 20-HETE on renal function may be due to 
the acute vs chronic manipulations of 20-HETE levels. In the experimental 
models to address the anti-hypertensive actions of 20-HETE, experiments were 
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done on wild type animals (Schwartzman et al., 1985; Nowicki et al., 1997; Amlal 
et al., 1998) or the Dahl salt-sensitive hypertensive rat (Ito and Roman, 1999). 
The changes in blood pressure have been induced either by exogenous 
administration of 20-HETE or pharmacological manipulations to endogenously 
increase 20-HETE. In mouse models with 20-HETE-dependent hypertension, 20-
HETE is elevated in renal microvessels (CC Wu et al., 2013) or urine (Gilani et 
al., 2020). 20-HETE in these animal models are constitutively elevated and the 
prolonged 20-HETE exposure is associated with compensatory changes in renal 
blood flow and salt reabsorption resulting in hypertension.  
The mechanism by which 20-HETE promotes smooth muscle cell 
contraction has been studied extensively. 20-HETE is able to inhibit the BKCa2+-
channel to increase levels of intracellular calcium (Lauterbach et al., 2002; 
Garcia et al., 2017). This action has been shown to be dependent on 20-HETE 
binding to its receptor (GPR75) (Garcia et al., 2017). 20-HETE can increase 
activity of Rho-kinase promoting the sensitization of smooth muscle cells to 
contraction (Randriamboavonjy et al., 2003). However, there are no current 
reports to suggest that this action is mediated by the 20-HETE receptor.  
Vascular smooth muscle cells have a unique property in which they can 
display one of two phenotypes. On one hand, they can exhibit a synthetic 
phenotype in which VSMC are capable of synthesizing proteins to induce 
migration and proliferation (D Stec et al., 2007; Orozco et al., 2013). On the other 
hand, VSMC can exhibit a contractile phenotype. The phenotype in which the 
VSMC is exhibiting can be shown through measurements of VSMC differentiation 
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markers. The markers used for the determination of the VSMC phenotype are: 
Myh11, Tagln, and Acta2 (Frismantiene et al., 2018). If the VSMC is exhibiting a 
synthetic phenotype, the expression of VSMC markers should be lower 
compared to controls. If the VSMC is exhibiting a contractile phenotype, the 
markers should be elevated compared to controls. The present study suggests 
that the Myh11-4a12 mice vessels are in a contractile phenotype (Frismantiene 
et al., 2018). Markers of VSMC differentiation were measured and mRNA levels 
of Myh11, Tagln, and Acta2 were all elevated compared to wild type mice. The 
elevated markers of VSMC differentiation suggest that there are more cells that 
are capable of contraction.  
To assess the cellular signaling involved in VSMC contraction, 
phosphorylation of myosin light chain (MLC) at serine 19 was performed. 
Phosphorylation of MLC is the downstream signaling event that needs to occur 
before excitation contraction coupling can occur in the VSMC (Driska et al., 
1981). Two reasons why MLC can remain phosphorylated include: 1) increase 
intracellular calcium promoting increase MLCK activity (Raina et al., 2009) and/or 
2) activation of ROCK signaling which inhibits myosin phosphatase and prevents 
the dephosphorylation of MLC (Noma et al., 2012). In the current study, ROCK 
expression and activity were assessed because it has not been determined if 20-
HETE-mediated changes in ROCK activity is receptor mediated.   
Myh11-4a12 mice had elevated phosphorylation levels compared to wild 
type and AAA treatment was able to reduce it. This suggests that myosin light 
chain phosphorylation is dependent on the 20-HETE receptor. ROCK1 protein 
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levels were measured and Myh11-4a12 mice treated with either vehicle or AAA 
had elevated levels compared to wild type animals. This indicates that ROCK1 
expression is not dependent on the 20-HETE receptor. If the 20-HETE receptor 
is not affecting ROCK expression, it may affect ROCK activity. Ex vivo 
experiments were performed in wild type mice to assess the mechanism in which 
20-HETE increases myogenic tone. The current report shows that 20-HETE 
shifts the internal diameter curve downward, suggesting an increase in myogenic 
tone. Co-administration of 20-HETE plus AAA or Rho-kinase inhibitor (Y-27632) 
shift the internal diameter curve upward similar to control values. Finally, co-
treatment of 20-HETE with AAA and Y-27632 had no further changes in 
myogenic tone. This suggests that Rho-kinase activity is acting downstream of 
the 20-HETE receptor to promote changes in the myogenic response.  
The finding above is similar to that in the report by Randriamboavonjy et. 
al. (2003). They determined that 20-HETE was capable of inducing contraction in 
small coronary arteries. Furthermore, they showed that small coronary arteries 
treated with 20-HETE had increased phosphorylation of MLC (Randriamboavonjy 
et al., 2003). The 20-HETE-induced phosphorylation of MLC was prevented with 
Y-27632 treatment. The findings from Randriamboavonjy study and the results 
from the present study suggests 20-HETE, through its receptor, is capable of 
promoting Rho-kinase activity, and allows for MLC phosphorylation, promoting 
VSMC contraction.  
Treatment of Myh11-4a12 mice with AAA was unable to reverse the 
remodeling phenotype in these mice. Media thickness and cross-sectional area 
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remained elevated after 12 days of AAA therapy. In addition, Myh11 protein 
expression was also unaffected with AAA treatment. In this model of 20-HETE 
overexpression, VSMCs are in the contractile phenotype rather than the 
synthetic. This was shown when comparing expression to smooth muscle-
specific differentiation markers. Myh11-4a12 had elevated Myh11, Tagln and 
Acta2 mRNA expression compared to wild types. If the VSMC were in a synthetic 
state, there should have been a reduction in the VSMC differentiation markers 
compared to WT mice (Frismantiene et al., 2018). The mouse model used in this 
experiment was a constitutive overexpression of Cyp4a12. It is possible that the 
proliferative phenotype occurred early in development and then switched to a 
contractile phenotype once the mouse reached adulthood.  
In other models of 20-HETE overexpression, the use of 20-HETE 
antagonists was able to prevent the remodeling phenotype (Ding et al., 2013; 
Garcia, et al., (2015b)). In these experimental models, 20-HETE was induced by 
DHT and was treated with a 20-HETE antagonist at the same time. 
Pharmacological antagonism of 20-HETE can prevent vascular remodeling in 20-
HETE-dependent models; however, 20-HETE antagonism may not be able to 
reverse remodeling after it has been established. Further studies will have to be 
performed to understand the mechanisms in which 20-HETE induces VSMC 
proliferation.   
Another finding in the present study was that Myh11-4a12 mice had 
impairment in NO signaling. When assessing phosphorylation of eNOS at Serine 
1177 in the aorta, Myh11-4a12 mice had lower phosphorylated eNOS levels 
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compared to wild type. The change in phosphorylated eNOS levels was 
attributed to a reduction in total eNOS expression in aorta. This observation was 
also shown in a rat model with endothelial specific Cyp4a2 overexpression 
(Inoue et al., 2009). The changes in phosphorylated eNOS expression in 
mesenteric arteries were attributed to changes in eNOS activity. Regardless, the 
reduction in eNOS phosphorylation will result in decreased NO bioavailability. 
The differences in changes in eNOS phosphorylation may be due to differences 
that can be observed in different vascular beds (Aird, 2007). Myh11-4a12 mice 
treated with AAA had elevated phosphorylated eNOS expression in both aorta 
and mesenteric arteries. Thus, changes in eNOS activation are due to 20-HETE 
acting through its receptor. 
The changes in eNOS phosphorylation were also accompanied by 
changes in VASP phosphorylation. VASP is a protein within the smooth muscle 
that is activated by PKG. Activation of PKG requires NO from the EC to diffuse to 
the VSMC to activate soluble guanylyl cyclase and increase cGMP. Thus, it can 
be used as a marker for NO signaling occurring within the VSMC (Oelze et al., 
2000). In aortas of Myh11-4a12 mice, there was a significant reduction of 
phosphorylated VASP compared to wild type. However, 12-day AAA therapy was 
not able to increase phosphorylated VASP in Myh11-4a12 mice. This result 
implies that other mechanisms may be present to reduce NO bioavailability that 
are unaffected by AAA treatment.     
At baseline values, Myh11-4a12 had impaired acetylcholine-induced 
relaxation that was restored when vessels were treated with sodium nitroprusside 
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(NO donor). This gives evidence that Myh11-4a12 mice have impairments in NO 
mediated vasodilation. One explanation that was shown in the present study was 
that eNOS activation was reduced. Another action that may have occurred is the 
increased production ROS. 20-HETE has been shown to increase ROS in both 
endothelium and VSMCs (Guo et al., 2007; Lakhkar et al., 2016). The generation 
of ROS can sequester NO away from the VSMC and prevent the activation of 
PKG.  
Within the EC and VSMC, 20-HETE has been documented to display 
different mechanisms in ROS generation. 20-HETE was shown to increase 
NADPH oxidase activity in pulmonary EC (Medhora et al., 2008); however, 20-
HETE in human umbilical vein EC and human microvascular EC display NADPH 
oxidase-independent ROS generation (Guo et al., 2007). 20-HETE was also 
shown to generate ROS in VSMC by promoting increased superoxide production 
by the mitochondria (Lakhkar et al., 2016). The differences in cell-specific 
mechanism of ROS generation may explain why increases in eNOS 
phosphorylation after AAA was not accompanied by increased VASP 
phosphorylation. It is possible that AAA was not able to ameliorate all the ROS-
generating effects of 20-HETE. Future studies will have to be performed in order 
to assess the mechanism of ROS generation in Myh11-4a12 mice and whether 
AAA is capable of changing ROS amounts.  
This study provides evidence that 20-HETE, through its receptor, is 
capable of increasing blood pressure and promoting changes in small artery 
vascular activity. One limitation of this study is that it cannot conclude that 20-
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HETE is acting through GPR75 to promote smooth muscle contraction. There are 
no current reports showing direct binding of AAA to GPR75; however, work is 
being done to show that AAA binds to GPR75 (unpublished data). The relevance 
of GPR75 can be assessed by using siRNA capable of downregulating GPR75 
expression. In the report by Garcia and colleagues (2017), they used siRNA to 
downregulate GPR75 expression in the vessels which promoted reductions in 
blood pressure and improvement in vascular reactivity. Furthermore, they 
showed that knock down of GPR75 reduced phosphorylation of the BKCa2+-
channel which inhibits the activity of the transporter (Garcia et al., 2017). Similar 
approaches can be used to assess the relevance of GPR75 on Rho-kinase 
activity. Furthermore, there are GPR75 global knockout and GPR75-flox mice 
that are available to further dissect the mechanisms in which GPR75 is involved.  
A second limitation of this study was that the mouse model used was a 
constitutive overexpression of Cyp4a12. Due to this, it cannot be determined 
whether 20-HETE is causing increases in blood pressure that promotes vascular 
remodeling or if 20-HETE is causing remodeling followed by increases in blood 
pressure. In one report, the investigators suggest that remodeling in vessels is 
independent in changes of blood pressure. 20-HETE overproduction was 
induced by DHT treatment and, in order to mitigate the increase in blood 
pressure, reserpine was administered (Ding et al., 2013). Mice treated with both 
DHT and reserpine experienced vascular remodeling without increases in blood 
pressure. The utilization of an inducible model of Cyp4a12 expression in the 
VSMC may be able to show 20-HETE’s contribution on blood pressure and 
 79 
vascular remodeling. There is a mouse line with cre-recombinase expression 
targeted in the VSMC that is inducible with tamoxifen treatment (Wirth et al., 
2008). Similar experiments can be performed in which mice can be co-
administered tamoxifen and AAA to determine if 20-HETE receptor antagonism 
can prevent remodeling in resistant vessels with Cyp4a12 overexpression. 
Furthermore, AAA can be administered after tamoxifen-induced Cyp4a12 
expression to determine if 20-HETE receptor antagonism can reverse the 
remodeling phenotype (Gilani et al., 2018). From these treatment groups, more 
insight can be obtained with regards to 20-HETE receptor-mediated actions to 
alter VSMC remodeling.  
Future experiments can be done to determine if AAA can reverse vascular 
remodeling. Twelve-day AAA treatment was not able to decrease RIA media 
thickness and cross-sectional area. One reason for AAA’s inability to reverse 
vascular remodeling is that the duration of treatment was too short to produce an 
effect. Vascular remodeling is a complex process that involves the production of 
new proteins to form a viable cell. These changes may take longer periods of 
time to produce a measurable effect. In addition, the VSMC that are present may 
take time to undergo apoptosis to reduce the number of cells within the vessel 
wall. There may be several mechanisms by which 20-HETE receptor antagonism 
can change signaling to inhibit VSMC proliferation.  
Another explanation in which AAA was unable to reverse the vascular 
remodeling phenotype may be due to 20-HETE promoting hypertrophy in 
addition to or rather then proliferation. 20-HETE has been documented to 
 80 
promote hypertrophy in cardiomyocytes that contributes to heart failure in 
experimental animals (El-Kadi and Zordoky, 2008; Zordoky et al., 2008). There 
are no reports to suggest that 20-HETE can contribute to hypertrophy in resistant 
vessels. It is possible that 20-HETE can promote hypertrophy due to its ability to 
increase ACE expression and activity followed by increased Ang II (Cheng et al., 
2012; Garcia et al., 2016). Furthermore, 20-HETE has been documented to 
activate mitogenic signaling that can also contribute to VSMC hypertrophy (Uddin 
et al., 1998; Muthalif et al., 2001). Further experimentation can be performed to 
assess 20-HETE action to promote hypertrophy and to determine if AAA is able 
to prevent it.  
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Perspective and Significance 
 Hypertension is a global burden of which approximately one fourth of the 
world population is diagnosed. Hypertension is a risk factor for several diseases 
including myocardial infarction, stroke, and renal failure. Although therapies are 
present such as ACE inhibitors/ARBS, diuretics and beta-blockers to control 
blood pressure there is a percentage of the population that do not respond to 
these therapies. Thus, there is a need to identify novel mechanisms that can be 
probed to improve blood pressure.  
 20-HETE has been extensively studied and consistently shows its role in 
blood pressure regulation. Actions include: 1) endothelial dysfunction, 2) elevated 
sodium reuptake; 3) VSMC contraction and proliferation. The multifaceted 
actions of 20-HETE on blood pressure make it an ideal target for blood pressure 
control. The use of pharmacological tools to either reduce the synthesis or inhibit 
the action of 20-HETE have shown positive effects on blood pressure and 
vascular function. What was not known until recently was how 20-HETE was able 
to initiate its downstream effects in the cell. The work of Garcia and colleagues 
(2017) was the first report to identify GPR75 as the receptor for 20-HETE. 
Identification of a novel GPCR for 20-HETE make it an attractive target for 
pharmacological manipulations. Future studies will be performed to fully 
characterize the actions of 20-HETE on blood pressure and vascular function 
through GPR75.  
 82 
References 
Aird WC (2007) Phenotypic heterogeneity of the endothelium: II. Representative 
vascular beds. Circ Res 100:174–190. 
 
Amlal H, Legoff C, Vernimmen C, Paillard M, and Bichara M (1996) Na+-
K+(NH4/+)-2Cl- cotransport in medullary thick ascending limb: Control by 
PKA, PKC, and 20-HETE. Am J Physiol - Cell Physiol 271:C455–C463. 
 
Amlal H, Legoff C, Vernimmen C, Soleimani M, Paillard M, and Bichara M (1998) 
ANG II controls Na-K (NH 4 )-2Cl cotransport via 20-HETE and PKC in 
medullary thick ascending limb. Am J Physiol - Cell Physiol 274:C1047–
C1056. 
 
Capdevila JH, and Falck JR (2000) Biochemical and molecular characteristics of 
the cytochrome P450 arachidonic acid monooxygenase. Prostaglandins 
Other Lipid Mediat 62:271–292. 
 
Cárdenas S, Colombero C, Panelo L, Dakarapu R, Falck JR, Costas MA, and 
Nowicki S (2020) GPR75 receptor mediates 20-HETE-signaling and 
metastatic features of androgen-insensitive prostate cancer cells. Biochim 
Biophys Acta - Mol Cell Biol Lipids 1865:1–14. 
 
Carroll, M. A., Sala, A., Dunn, C.E., McGiff, J.C.  and MRC (1991) Structural 
identification of cytochrome P450-dependent arachidonate metabolites 
formed by rabbit medullary thick ascending limb cells. J Biol Chem 
226:12306–12312. 
 
CDC (2020) High Blood Pressure Symptoms and Causes | cdc.gov. 
 
Chen L, Ackerman R, Saleh M, Gotlinger KH, Kessler M, Mendelowitz LG, Falck 
JR, Arbab AS, Scicli AG, Schwartzman ML, Yang J, and Guo AM (2014) 20-
HETE regulates the angiogenic functions of human endothelial progenitor 
cells and contributes to angiogenesis in vivo. J Pharmacol Exp Ther 
348:442–451. 
 
Chen L, Joseph G, Zhang FF, Nguyen H, Jiang H, Gotlinger KH, Falck JR, Yang 
J, Schwartzman ML, and Guo AM (2016) 20-HETE contributes to ischemia-
induced angiogenesis. Vascul Pharmacol 83:57–65. 
 
Cheng J, Edin ML, Hoopes SL, Li H, Bradbury JA, Graves JP, DeGraff LM, Lih 
FB, Garcia V, Shaik JSB, Tomer KB, Flake GP, Falck JR, Lee CR, Poloyac 
SM, Schwartzman ML, and Zeldin DC (2014) Vascular characterization of 




Cheng J, Garcia V, Ding Y, Wu C-C, Thakar K, Falck JR, Ramu E, and 
Schwartzman ML (2012) Induction of angiotensin-converting enzyme and 
activation of the renin-angiotensin system contribute to 20-
hydroxyeicosatetraenoic acid-mediated endothelial dysfunction. Arterioscler 
Thromb Vasc Biol 32:1917–24. 
 
Cheng J, Ou J-S, Singh H, Falck JR, Narsimhaswamy D, Pritchard KA, and 
Schwartzman ML (2008) 20-Hydroxyeicosatetraenoic acid causes 
endothelial dysfunction via eNOS uncoupling. Am J Physiol - Circ Physiol 
294:H1018–H1026. 
 
Cheng J, Wu C-C, Gotlinger KH, Zhang F, Falck JR, Narsimhaswamy D, and 
Schwartzman ML (2010) 20-hydroxy-5,8,11,14-eicosatetraenoic acid 
mediates endothelial dysfunction via IkappaB kinase-dependent endothelial 
nitric-oxide synthase uncoupling. J Pharmacol Exp Ther 332:57–65. 
 
Christmas P, Jones JP, Patten CJ, Rock DA, Zheng Y, Cheng S-M, Weber BM, 
Carlesso N, Scadden DT, Rettie AE, and Soberman RJ (2001) Alternative 
Splicing Determines the Function of CYP4F3 by Switching Substrate 
Specificity*. J Biol Chem 276:38166–72. 
 
Chuang SS, Helvig C, Taimi M, Ramshaw HA, Collop AH, Amad M, White JA, 
Petkovich M, Jones G, and Korczak B (2004) CYP2U1, a Novel Human 
Thymus- and Brain-specific Cytochrome P450, Catalyzes ω- and (ω-1)-
Hydroxylation of Fatty Acids. J Biol Chem 279:6305–6314. 
 
Costa TJ, Ceravolo GS, Echem C, Hashimoto CM, Costa BP, Santos-Eichler RA, 
Oliveira MA, Jiménez-Altayó F, Akamine EH, Dantas AP, and Carvalho MHC 
(2018) Detrimental effects of testosterone addition to estrogen therapy 
involve cytochrome P-450-induced 20-HETE synthesis in aorta of 
ovariectomized spontaneously hypertensive rat (SHR), a model of 
postmenopausal hypertension. Front Physiol 9:1–13. 
 
Croft KD, McGiff JC, Sanchez-Mendoza A, and Carroll MA (2000) Angiotensin II 
releases 20-HETE from rat renal microvessels. Am J Physiol - Renal Physiol 
279:F544–F551. 
 
Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black 
HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, 
Wright JT, Alderman MH, Weiss RJ, Piller L, Bettencourt J, and Walsh SM 
(2002) Success and predictors of blood pressure control in diverse North 
American settings: The antihypertensive and lipid-lowering treatment to 





Davis MJ, Meininger GA, and Zawieja DC (1992) Stretch-induced increases in 
intracellular calcium of isolated vascular smooth muscle cells. Am J Physiol - 
Hear Circ Physiol 263:32–4. 
 
Dedoni S, Campbell LA, Harvey BK, Avdoshina V, and Mocchetti I (2018) The 
orphan G‐protein‐coupled receptor 75 signaling is activated by the 
chemokine CCL5. J Neurochem 146:526–539. 
 
Ding Y, Wu C-C, Garcia V, Dimitrova I, Weidenhammer A, Joseph G, Zhang F, 
Manthati VL, Falck JR, Capdevila JH, and Schwartzman ML (2013) 20-
HETE induces remodeling of renal resistance arteries independent of blood 
pressure elevation in hypertension. Am J Physiol - Renal Physiol 305:F753–
F763. 
 
Driska SP, Aksoy MO, and Murphy RA (1981) Myosin light chain phosphorylation 
associated with contraction in arterial smooth muscle. Am J Physiol - Cell 
Physiol 9:C222-233. 
 
Dunn KM, Renic M, Flasch AK, Harder DR, Falck J, Roman Richard J, and 
Roman R J (2008) Elevated production of 20-HETE in the cerebral 
vasculature contributes to severity of ischemic stroke and oxidative stress in 
spontaneously hypertensive rats. Am J Physiol - Hear Circ Physiol 
295:2455–2465. 
 
El-Kadi A, and Zordoky B (2008) Modulation of Cardiac and Hepatic Cytochrome 
P450 Enzymes During Heart Failure. Curr Drug Metab 9:122–128. 
 
Escalante B, Erlij D, Falck JR, and McGiff JC (1994) Cytochrome P-450 
arachidonate metabolites affect ion fluxes in rabbit medullary thick 
ascending limb. Am J Physiol - Cell Physiol 266:C1775-1782. 
 
Escalante B, Erlij D, Falck JR, and McGiff JC (1991) Effect of cytochrome P450 
arachidonate metabolites on ion transport in rabbit kidney loop of Henle. 
Science 251:799–802. 
 
Fan F, Sun C-W, Maier KG, Williams JM, Pabbidi MR, Didion SP, Falck JR, Zhuo 
J, and Roman RJ (2013) 20-Hydroxyeicosatetraenoic Acid Contributes to the 
Inhibition of K+ Channel Activity and Vasoconstrictor Response to 
Angiotensin II in Rat Renal Microvessels. PLoS One 8:1–20. 
 
Fishel RS, Eisenberg S, Shai S-Y, Redden RA, Bernstein KE, and Berk BC 
(1995) Glucocorticoids Induce Angiotensin-Converting Enzyme Expression 





Frismantiene A, Philippova M, Erne P, and Resink TJ (2018) Smooth muscle 
cell-driven vascular diseases and molecular mechanisms of VSMC plasticity. 
Cell Signal 52:48–64. 
 
Garcia V, Cheng J, Weidenhammer A, Ding Y, Wu CC, Zhang F, Gotlinger K, 
Falck JR, and Schwartzman ML (2015) Androgen-induced hypertension in 
angiotensinogen deficient mice: Role of 20-HETE and EETS. Prostaglandins 
Other Lipid Mediat 116–117:124–130. 
 
Garcia V, Gilani A, Shkolnik B, Pandey V, Zhang FF, Dakarapu R, Gandham SK, 
Reddy NR, Graves JP, Gruzdev A, Zeldin DC, Capdevila JH, Falck JR, and 
Schwartzman ML (2017) 20-HETE Signals Through G-Protein–Coupled 
Receptor GPR75 (G q ) to Affect Vascular Function and Trigger 
Hypertension. Circ Res 120:1776–1788. 
 
Garcia V, Joseph G, Shkolnik B, Ding Y, Zhang FF, Gotlinger K, Falck JR, 
Dakarapu R, Capdevila JH, Bernstein KE, and Schwartzman ML (2015) 
Angiotensin II receptor blockade or deletion of vascular endothelial ACE 
does not prevent vascular dysfunction and remodeling in 20-HETE-
dependent hypertension. Am J Physiol - Integr Comp Physiol 309:R71–R78. 
 
Garcia V, Shkolnik B, Milhau L, Falck JR, and Schwartzman ML (2016) 20-HETE 
Activates the Transcription of Angiotensin-Converting Enzyme via Nuclear 
Factor-κB Translocation and Promoter Binding. J Pharmacol Exp Ther 
356:525–33. 
 
Gawrys O, Husková Z, Baranowska I, Walkowska A, Sadowski J, Kikerlová S, 
Vaňourková Z, Honetschlägerová Z, Škaroupková P, Červenka L, Falck JR, 
Imig JD, and Kompanowska-Jezierska E (2020) Combined treatment with 
epoxyeicosatrienoic acid analog and 20-hydroxyeicosatetraenoic acid 
antagonist provides substantial hypotensive effect in spontaneously 
hypertensive rats. J Hypertens 38:1802–1810. 
 
Gebremedhin D, Lange AR, Lowry TF, Taheri MR, Birks EK, Hudetz AG, 
Narayanan J, Falck JR, Okamoto H, Roman RJ, Nithipatikom K, Campbell 
WB, and Harder DR (2000) Production of 20-HETE and Its Role in 
Autoregulation of Cerebral Blood Flow. Circ Res 87:60–65. 
 
Gebremedhin D, Lange AR, Narayanan J, Aebly MR, Jacobs ER, and Harder DR 
(1998) Cat cerebral arterial smooth muscle cells express cytochrome P450 
4A2 enzyme and produce the vasoconstrictor 20-HETE which enhances L-






Gilani A, Agostinucci K, Hossain S, Pascale J V., Garcia V, Adebesin AM, Falck 
JR, and Schwartzman ML (2021) 20-HETE Interferes with Insulin Signaling 
and Contributes to Obesity-Driven Insulin Resistance. Prostaglandins Other 
Lipid Mediat 152:1–10. 
 
Gilani A, Agostinucci K, Pascale J V., Hossain S, Kandhi S, Pandey V, Garcia V, 
Nasjletti A, and Laniado Schwartzman M (2020) Proximal tubule-targeted 
overexpression of the Cyp4a12-20-HETE synthase promotes salt-sensitive 
hypertension in male mice. Am J Physiol - Integr Comp Physiol 319:R87–
R95. 
 
Gilani A, Pandey V, Garcia V, Agostinucci K, Singh SP, Schragenheim J, Bellner 
L, Falck JR, Paudyal MP, Capdevila JH, Abraham NG, and Laniado 
Schwartzman M (2018) High-fat diet-induced obesity and insulin resistance 
in CYP4a14 −/− mice is mediated by 20-HETE. Am J Physiol - Integr Comp 
Physiol 315:R934–R944. 
 
Gonzalez-Fernandez E, Staursky D, Lucas K, Nguyen B V., Li M, Liu Y, 
Washington C, Coolen LM, Fan F, and Roman RJ (2020) 20-HETE 
Enzymes and Receptors in the Neurovascular Unit: Implications in 
Cerebrovascular Disease. Front Neurol 11:1–19. 
 
Gosmanova EO, Mikkelsen MK, Molnar MZ, Lu JL, Yessayan LT, Kalantar-
Zadeh K, and Kovesdy CP (2016) Association of Systolic Blood Pressure 
Variability With Mortality, Coronary Heart Disease, Stroke, 
and Renal Disease. J Am Coll Cardiol 68:1375–1386. 
 
Guo AM, Arbab AS, Falck JR, Chen P, Edwards PA, Roman RJ, and Scicli AG 
(2007) Activation of vascular endothelial growth factor through reactive 
oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced 
endothelial cell proliferation. J Pharmacol Exp Ther 321:18–27. 
 
Guo AM, Scicli G, Sheng J, Falck JC, Edwards PA, and Scicli AG (2009) 20-
HETE can act as a nonhypoxic regulator of HIF-1α in human microvascular 
endothelial cells. Am J Physiol - Circ Physiol 297:H602–H613. 
 
Harder DR, Gebremedhin D, Narayanan J, Jefcoat C, Falck JR, Campbell WB, 
and Roman R (1994) Formation and action of a P-450 4A metabolite of 
arachidonic acid in cat cerebral microvessels. Am J Physiol - Hear Circ 
Physiol 266:H2098-2107. 
 
Hardwick JP (2008) Cytochrome P450 omega hydroxylase (CYP4) function in 





Hercule HC, and Oyekan AO (2000) Cytochrome P450 /-1 Hydroxylase-Derived 
Eicosanoids Contribute to Endothelin A and Endothelin B Receptor-
Mediated Vasoconstriction to Endothelin-1 in the Rat Preglomerular Arteriole 
1. J Pharmacol Exp Ther 292:1153–1160. 
 
Holla VR, Adas F, Imig JD, Zhao X, Price E, Olsen N, Kovacs WJ, Magnuson 
MA, Keeney DS, Breyer MD, Falck JR, Waterman MR, and Capdevila JH 
(2001) Alterations in the regulation of androgen-sensitive Cyp 4a 
monooxygenases cause hypertension. Proc Natl Acad Sci U S A 98:5211–
5216. 
 
Huang Z, Jiang Y, and Zhou Y (2020) The role of cytochrome P450 gene 
rs1126742 polymorphism and risk of hypertension: A systematic review and 
meta-analysis. Biosci Rep 40:1–10. 
 
Ignatov A, Robert J, Gregory-Evans C, and Schaller HC (2006) RANTES 
stimulates Ca 2+ mobilization and inositol trisphosphate (IP3) formation in 
cells transfected with G protein-coupled receptor 75. Br J Pharmacol 
149:490–497. 
 
Inoue K, Sodhi K, Puri N, Gotlinger KH, Cao J, Rezzani R, Falck JR, Abraham 
NG, and Laniado-Schwartzman M (2009) Endothelial-specific CYP4A2 
overexpression leads to renal injury and hypertension via increased 
production of 20-HETE. Am J Physiol - Renal Physiol 297:F875–F884. 
 
Ishizuka T, Cheng J, Singh H, Vitto MD, Manthati VL, Falck JR, and Laniado-
Schwartzman M (2008) 20-Hydroxyeicosatetraenoic acid stimulates nuclear 
factor-κB activation and the production of inflammatory cytokines in human 
endothelial cells. J Pharmacol Exp Ther 324:103–110. 
 
Ito O, and Roman RJ (1999) Role of 20-HETE in elevating chloride transport in 
the thick ascending limb of Dahl SS/Jr rats. Hypertension 33:419–423. 
 
Joseph G, Soler A, Hutcheson R, Hunter I, Bradford C, Hutcheson B, Gotlinger 
KH, Jiang H, Falck JR, Proctor S, Schwartzman ML, and Rocic P (2017) 
Elevated 20-HETE impairs coronary collateral growth in metabolic syndrome 
via endothelial dysfunction. Am J Physiol - Hear Circ Physiol 312:H528–
H540. 
 
Kaide JI, Zhang F, Wei Y, Wang WH, Gopal VR, Falck JR, Laniado-
Schwartzman M, and Nasjletti A (2004) Vascular CO counterbalances the 






Kalyankrishna S, and Malik KU (2003) Norepinephrine-induced stimulation of p38 
mitogen-activated protein kinase is mediated by arachidonic acid 
metabolites generated by activation of cytosolic phospholipase A2 in 
vascular smooth muscle cells. J Pharmacol Exp Ther 304:761–772. 
 
Laffer CL, Gainer J V., Waterman MR, Capdevila JH, Laniado-Schwartzman M, 
Nasjletti A, Brown NJ, and Elijovich F (2008) The T8590C polymorphism of 
CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hypertension. 
Hypertension 51:767–772. 
 
Laffer CL, Laniado-Schwartzman M, Wang MH, Nasjletti A, and Elijovich F 
(2003) Differential regulation of natriuresis by 20-hydroxyeicosatetraenoic 
acid in human salt-sensitive versus salt-resistant hypertension. Circulation 
107:574–578. 
 
Lai G, Wu J, Liu X, and Zhao Y (2012) 20-HETE Induces Hyperglycemia through 
the cAMP/PKA-PhK-GP Pathway. Mol Endocrinol 26:1907–1916. 
 
Lakhkar A, Dhagia V, Joshi SR, Gotlinger K, Patel D, Sun D, Wolin MS, 
Schwartzman ML, and Gupte SA (2016) 20-HETE-induced mitochondrial 
superoxide production and inflammatory phenotype in vascular smooth 
muscle is prevented by glucose-6-phosphate dehydrogenase inhibition. Am 
J Physiol - Circ Physiol 310:H1107–H1117. 
 
Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, and Powell PK (2000) 
Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic 
eicosanoid, in human kidney. Role of CYP4F2 and CYP4A11. J Biol Chem 
275:4118–4126. 
 
Lauterbach B, Barbosa-Sicard E, Wang M-H, Honeck H, Kärgel E, Theuer J, 
Schwartzman ML, Haller H, Luft FC, Gollasch M, and Schunck W-H (2002) 
Cytochrome P450-Dependent Eicosapentaenoic Acid Metabolites Are Novel 
BK Channel Activators. Hypertension 39:609–613 
 
Li JS, Larivière R, and Schiffrin EL (1994) Effect of a nonselective endothelin 
antagonist on vascular remodeling in deoxycorticosterone acetate-salt 
hypertensive rats: Evidence for a role of endothelin in vascular hypertrophy. 
Hypertension 24:183–188. 
 
Li X, Zhao G, Ma B, Li R, Hong J, Liu S, and Wang DW (2014) 20-
Hydroxyeicosatetraenoic acid impairs endothelial insulin signaling by 
inducing phosphorylation of the insulin receptor substrate-1 at Ser 616. 





Lin F, Rios A, Falck JR, Belosludtsev Y, and Schwartzman ML (1995) 20-
hydroxyeicosatetraenoic acid is formed in response to EGF and is a mitogen 
in rat proximal tubule. Am J Physiol - Ren Fluid Electrolyte Physiol 
269:F806–F816. 
 
Liu B, Hassan Z, Amisten S, King AJ, Bowe JE, Huang GC, Jones PM, and 
Persaud SJ (2013) The novel chemokine receptor, G-protein-coupled 
receptor 75, is expressed by islets and is coupled to stimulation of insulin 
secretion and improved glucose homeostasis. Diabetologia 56:2467–2476. 
 
Medhora M, Chen Y, Gruenloh S, Harland D, Bodiga S, Zielonka J, Gebremedhin 
D, Gao Y, Falck JR, Anjaiah S, and Jacobs ER (2008) 20-HETE increases 
superoxide production and activates NAPDH oxidase in pulmonary artery 
endothelial cells. Am J Physiol - Cell Mol Physiol 294:L902–L911. 
 
Muller DN, Schmidt C, Barbosa-Sicard E, Wellner M, Gross V, Hercule H, 
Markovic M, Honeck H, Luft FC, and Schunck WH (2007) Mouse Cyp4a 
isoforms: Enzymatic properties, gender- and strain-specific expression, and 
role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem J 403:109–
118. 
 
Muthalif MM, Benter IF, Uddin MR, and Malik KU (1996) Calcium/calmodulin-
dependent protein kinase IIα mediates activation of mitogen-activated 
protein kinase and cytosolic phospholipase A2 in norepinephrine-induced 
arachidonic acid release in rabbit aortic smooth muscle cells. J Biol Chem 
271:30149–30157. 
 
Muthalif MM, Uddin MR, Fatima S, Parmentier JH, Khandekar Z, and Malik KU 
(2001) Small GTP binding protein Ras contributes to norepinephrine-induced 
mitogenesis of vascular smooth muscle cells. Prostaglandins Other Lipid 
Mediat 65:33–43. 
 
Nguyen X, Wang M-H, Reddy KM, Falck JR, and Schwartzman ML (1999) 
Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and 
isoform-specific inhibitors. Am J Physiol - Integr Comp Physiol 276:R1691–
R1700. 
 
Noma K, Kihara Y, and Higashi Y (2012) Striking crosstalk of ROCK signaling 
with endothelial function. J Cardiol 60:1–6. 
 
Nowicki S, Chen SL, Aizman O, Cheng XJ, Li D, Nowicki C, Nairn A, Greengard 
P, and Aperia A (1997) 20-Hydroxyeicosa-tetraenoic acid (20 HETE) 
activates protein kinase C. Role in regulation of rat renal Na+,K+-ATPase. J 




Oelze M, Mollnau H, Hoffmann N, Warnholtz A, Bodenschatz M, Smolenski A, 
Walter U, Skatchkov M, Meinertz T, and Münzel T (2000) Vasodilator-
stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor 
of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ 
Res 87:999–1005. 
 
Omata K, Abraham NG, and Schwartzman ML (1992) Renal cytochrome P-450-
arachidonic acid metabolism: Localization and hormonal regulation in SHR. 
Am J Physiol - Ren Fluid Electrolyte Physiol 262:F591–F599. 
 
Orozco LD, Liu H, Perkins E, Johnson DA, Chen BB, Fan F, Baker RC, and 
Roman RJ (2013) 20-hydroxyeicosatetraenoic acid inhibition attenuates 
balloon injury-induced neointima formation and vascular remodeling in rat 
carotid arteries. J Pharmacol Exp Ther 346:67–74. 
 
Padmanabhan S, Wallace C, Munroe PB, Dobson R, Brown M, Samani N, 
Clayton D, Farrall M, Webster J, Lathrop M, Caulfield M, Dominiczak AF, 
and Connell JM (2006) Chromosome 2p shows significant linkage to 
antihypertensive response in the British genetics of hypertension study. 
Hypertension 47:603–608. 
 
Pandey V, Garcia V, Gilani A, Mishra P, Zhang FF, Paudyal MP, Falck JR, 
Nasjletti A, Wang W-H, and Schwartzman ML (2017) The Blood Pressure-
Lowering Effect of 20-HETE Blockade in Cyp4a14(-/-) Mice Is Associated 
with Natriuresis. J Pharmacol Exp Ther 363:412–418. 
 
Parmentier JH, Muthalif MM, Saeed AE, and Malik KU (2001) Phospholipase D 
activation by norepinephrine is mediated by 12(S)-, 15(S)-, and 20-
hydroxyeicosatetraenoic acids generated by stimulation of cytosolic 
phospholipase A2: Tyrosine phosphorylation of phospholipase D 2 in 
response to norepinephrine. J Biol Chem 276:15704–15711. 
 
Pease JE (2006) Tails of the unexpected - an atypical receptor for the chemokine 
RANTES/CCL5 expressed in brain. Br J Pharmacol 149:460–462. 
 
Powell PK, Wolf I, Jin R, and Lasker JM (1998) Metabolism of Arachidonic Acid 
to 20-Hydroxy-5,8,11,14-eicosatetraenoic Acid by P450 Enzymes in Human 
Liver: Involvement of CYP4F2 and CYP4A11. J Pharmacol Exp Ther 
285:1327–1336. 
 
Quigley R, Chakravarty S, Zhao X, Imig JD, and Capdevila JH (2009) Increased 
Renal Proximal Convoluted Tubule Transport Contributes to Hypertension in 





Raina H, Zacharia J, Li M, and Wier WG (2009) Activation by Ca2+/calmodulin of 
an exogenous myosin light chain kinase in mouse arteries. J Physiol 
587:2599–2612. 
Randriamboavonjy V, Busse R, and Fleming I (2003) 20-HETE-induced 
contraction of small coronary arteries depends on the activation of Rho-
kinase. Hypertension 41:801–806. 
Ribeiro CMP, Dubay GR, Falck JR, and Mandel LJ (1994) Parathyroid hormone 
inhibits Na+-K+-ATPase through a cytochrome P-450 pathway. Am J Physiol 
- Ren Fluid Electrolyte Physiol 266:F497–F505.
Rocic P, and Schwartzman ML (2018) 20-HETE in the regulation of vascular and 
cardiac function. Pharmacol Ther 192:74–87. 
Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of 
cardiovascular function. Physiol Rev 82:131–185. 
Roman RJ, and Kaldunski ML (1991) Enhanced Chloride Reabsorption in the 
Loop of Henle in Dahl Salt-Sensitive Rats. Hypertension 17:1018–1024. 
Roman RJ, Ma YH, Frohlich B, and Markham B (1993) Clofibrate prevents the 
development of hypertension in dahl salt-sensitive rats. Hypertension 
21:985–9788. 
Rosolowsky M, Falck JR, and Campbell WB (1996) Metabolism of arachidonic 
acid by canine polymorphonuclear leukocytes synthesis of lipoxygenase and 
omega-oxidized metabolites. Biochim Biophys Acta - Lipids Lipid Metab 
1300:143–150. 
Sacerdoti D, Escalante B, Abraham NG, Mcgiff JC, Levere RD, and 
Schwartzman ML (1989) Treatment with tin prevents the development of 
hypertension in spontaneously hypertensive rats. Science 243:388–390. 
Savas Ü, Wei S, Hsu M-H, Falck JR, Guengerich FP, Capdevila JH, and 
Johnson EF (2016) 20-Hydroxyeicosatetraenoic acid (HETE)-dependent 
hypertension in human cytochrome P450 (CYP) 4A11 transgenic mice: 
Normalization of blood pressure by sodium restriction, hydrochlorothiazide, 
or blockade of the type 1 angiotensin II receptor. J Biol Chem 291:16904–
16919. 
Schwartzman M, Ferreri NR, Carroll MA, Songu-Mize E, and McGiff JC (1985) 
 Renal cytochrome P450-related arachidonate metabolite inhibits (Na+ 
K+)ATPase. Nature 314:620–622. 
 92 
Sedláková L, Kikerlová S, Husková Z, Červenková L, Chábová VČ, Zicha J, 
Falck JR, Imig JD, Kompanowska-Jezierska E, Sadowski J, Krátký V, 
Červenka L, and Kopkan L (2018) 20-Hydroxyeicosatetraenoic acid 
antagonist attenuates the development of malignant hypertension and 
reverses it once established: A study in Cyp1a1-Ren-2 transgenic rats. 
Biosci Rep 38:1–16. 
 
Silverstein DM, Barac-Nieto M, Falck JR, and Spitzer A (1998) 20-HETE 
mediates the effect of parathyroid hormone and protein kinase C on renal 
phosphate transport. Prostaglandins Leukot Essent Fat Acids 58:209–213. 
 
Singh H, Cheng J, Deng H, Kemp R, Ishizuka T, Nasjletti A, and Schwartzman 
ML (2007) Vascular cytochrome P450 4A expression and 20-
hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction 
in androgen-induced hypertension. Hypertens 50:123–9. 
 
Sodhi K, Wu C-C, Cheng J, Gotlinger K, Inoue K, Goli M, Falck JR, Abraham 
NG, and Schwartzman ML (2010) CYP4A2-induced hypertension is 20-
hydroxyeicosatetraenoic acid- and angiotensin II-dependent. Hypertens  
56:871–8. 
 
Soler A, Hunter I, Joseph G, Hutcheson R, Hutcheson B, Yang J, Zhang FF, 
Joshi SR, Bradford C, Gotlinger KH, Maniyar R, Falck JR, Proctor S, 
Schwartzman ML, Gupte SA, and Rocic P (2018) Elevated 20-HETE in 
metabolic syndrome regulates arterial stiffness and systolic hypertension via 
MMP12 activation. J Mol Cell Cardiol 117:88–99. 
 
Stec D, Gannon K, Beaird J, and Drummond H (2007) 20-
Hydroxyeicosatetraenoic Acid (20-HETE) Stimulates Migration of Vascular 
Smooth Muscle Cells. Cell Physiol Biochem 19:121–128. 
 
Stec DE, Deng AY, Rapp JP, and Roman RJ (1996) Cytochrome P4504A 
genotype cosegregates with hypertension in Dahl S rats. Hypertension 
27:564–568. 
 
Stec DE, Roman RJ, Flasch A, and Rieder MJ (2007) Functional polymorphism 
in human CYP4F2 decreases 20-HETE production. Physiol Genomics 
30:74–81. 
 
Swärd K, Mita M, Wilson DP, Deng JT, Susnjar M, and Walsh MP (2003) The 
role of RhoA and Rho-associated kinase in vascular smooth muscle 






Tansey MG, Luby-Phelps K, Kamm KE, and Stull JT (1994) Ca2+-dependent 
phosphorylation of myosin light chain kinase decreases the Ca2+ sensitivity 
of light chain phosphorylation within smooth muscle cells. J Biol Chem 
269:9912–9920. 
 
Tarttelin EE, Kirschner LS, Bellingham J, Baffi J, Taymans SE, Gregory-Evans K, 
Csaky K, Stratakis CA, and Gregory-Evans CY (1999) Cloning and 
characterization of a novel orphan G-protein-coupled receptor localized to 
human chromosome 2p16. Biochem Biophys Res Commun 260:174–180. 
 
Toth P, Csiszar A, Tucsek Z, Sosnowska D, Gautam T, Koller A, Schwartzman 
ML, Sonntag WE, and Ungvari Z (2013) Role of 20-HETE, TRPC channels, 
and BKCa2+ in dysregulation of pressure-induced Ca2+ signaling and 
myogenic constriction of cerebral arteries in aged hypertensive mice. Am J 
Physiol - Circ Physiol 305:H1698–H1708. 
 
Tsai IJ, Croft KD, Puddey IB, Beilin LJ, and Barden A (2011) 20-
Hydroxyeicosatetraenoic acid synthesis is increased in human neutrophils 
and platelets by angiotensin II and endothelin-1. Am J Physiol - Circ Physiol 
300:H1194–H1200. 
 
Tunaru S, Bonnavion R, Brandenburger I, Preussner J, Thomas D, Scholich K, 
and Offermanns S (2018) 20-HETE promotes glucose-stimulated insulin 
secretion in an autocrine manner through FFAR1. Nat Commun 9:1–11. 
 
Uddin MR, Muthalif MM, Karzoun NA, Benter IF, and Malik KU (1998) 
Cytochrome P-450 Metabolites Mediate Norepinephrine-Induced Mitogenic 
Signaling. Hypertension 31:242–247. 
 
Walkowska A, Červenka L, Imig JD, Falck JR, Sadowski J, and Kompanowska-
Jezierska E (2021) Early Renal Vasodilator and Hypotensive Action of 
Epoxyeicosatrienoic Acid Analog (EET-A) and 20-HETE Receptor Blocker 
(AAA) in Spontaneously Hypertensive Rats. Front Physiol 12:1–16. 
 
Wang J-S, Singh H, Zhang F, Ishizuka T, Deng H, Kemp R, Wolin MS, Hintze 
TH, Abraham NG, Nasjletti A, and Laniado-Schwartzman M (2006) 
Endothelial Dysfunction and Hypertension in Rats Transduced With CYP4A2 
Adenovirus. Circ Res 98:962–969. 
 
Wang M-H, Wang J, Chang H-H, Zand BA, Jiang M, Nasjletti A, and Laniado-
Schwartzman M (2003) Regulation of renal CYP4A expression and 20-






Wang Y, Zheng XR, Riddick N, Bryden M, Baur W, Zhang X, and Surks HK 
(2009) ROCk isoform regulation of myosin phosphatase and contractility in 
vascular smooth muscle cells. Circ Res 104:531–540. 
 
Ward NC, Rivera J, Hodgson J, Puddey IB, Beilin LJ, Falck JR, and Croft KD 
(2004) Urinary 20-hydroxyeicosatetraenoic acid is associated with 
endothelial dysfunction in humans. Circulation 110:438–443. 
 
Ward NC, Tsai IJ, Barden A, Van Bockxmeer FM, Puddey IB, Hodgson JM, and 
Croft KD (2008) A single nucleotide polymorphism in the CYP4F2 but not 
CYP4A11 gene is associated with increased 20-HETE excretion and blood 
pressure. Hypertension 51:1393–1398. 
 
Wirth A, Benyó Z, Lukasova M, Leutgeb B, Wettschureck N, Gorbey S, Orsy P, 
Horváth B, Maser-Gluth C, Greiner E, Lemmer B, Schütz G, Gutkind S, and 
Offermanns S (2008) G12-G13-LARG-mediated signaling in vascular 
smooth muscle is required for salt-induced hypertension. Nat Med 14:64–68. 
 
Wu CC, Mei S, Cheng J, Ding Y, Weidenhammer A, Garcia V, Zhang F, 
Gotlinger K, Manthati VL, Falck JR, Capdevila JH, and Schwartzman ML 
(2013) Androgen-sensitive hypertension associates with upregulated 
vascular CYP4A12-20-HETE synthase. J Am Soc Nephrol 24:1288–1296. 
 
Wu J, Liu X, Lai G, Yang X, Wang L, and Zhao Y (2013) Synergistical effect of 
20-HETE and high salt on NKCC2 protein and blood pressure via ubiquitin-
proteasome pathway. Hum Genet 132:179–187. 
 
Xin HB, Deng KY, Rishniw M, Ji G, and Kotlikoff MI (2002) Smooth muscle 
expression of Cre recombinase and eGFP in transgenic mice. Physiol 
Genomics 2002:211–215. 
 
Zhang F, Wang M-H, Krishna UM, Falck JR, Laniado-Schwartzman M, and 
Nasjletti A (2001) Modulation by 20-HETE of Phenylephrine-Induced 
Mesenteric Artery Contraction in Spontaneously Hypertensive and Wistar-
Kyoto Rats. Hypertension 38:1311–1315. 
 
Zhu D, Zhang C, Medhora M, and Jacobs ER (2002) CYP4A mRNA, protein, and 
product in rat lungs: novel localization in vascular endothelium. J Appl 
Physiol 93:330–337. 
 
Zordoky BNM, Aboutabl ME, and El-Kadi AOS (2008) Modulation of cytochrome 
P450 gene expression and arachidonic acid metabolism during 





Zou AP, Fleming JT, Falck JR, Jacobs ER, Gebremedhin D, Harder DR, and 
Roman RJ (1996) 20-HETE is an endogenous inhibitor of the large-
conductance Ca2+-activated K+ channel in renal arterioles. Am J Physiol - 
Regul Integr Comp Physiol 270:R228–R237,. 
 
Zou AP, Imig JD, Kaldunski M, De Montellano PRO, Sui Z, and Roman RJ 
(1994) Inhibition of renal vascular 20-HETE production impairs 
autoregulation of renal blood flow. Am J Physiol - Ren Fluid Electrolyte 
Physiol 266:F275–F282. 
 
